A microtubule depolymerizing agent and its preparation method and use

By synthesizing microtubule depolymerizers with hydroxamic acid structure, the problems of toxic side effects and drug resistance of existing microtubule binding agents are solved, and effective inhibition of a variety of tumor cells, especially drug-resistant cells are achieved. And overcome the synthesis problems of large molecular weight and complex structure.

CN115772130BActive Publication Date: 2024-11-08WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111052529.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-08
Publication Date
2024-11-08
Estimated Expiration
2041-09-08

AI Technical Summary

Technical Problem

The existing tubulin binding agents used in tumor treatment have large toxic side effects and drug resistance problems. They are large in molecular weight and complex in structure, making it difficult to synthesize and modify, especially microtubule depolymerization agents at colchicine sites have not been found yet. Reports of hydroxamic acid structure.

Method used

Provide a microtubule depolymerization agent that depends on hydroxamic acid. By synthesizing compounds 7b-14b, the hydroxamic acid group is used to show good inhibitory effects on various tumor cells, and overcome the existing microtubule decomposition. Poisonous side effects and drug resistance problems of polymerizers.

Benefits of technology

Compound 7b-14b shows excellent anti-tumor activity, especially effective for drug-resistant tumor cells, good metabolic stability, small toxic and side effects, and has broad-spectrum anti-tumor effects. It is suitable for the treatment of a variety of tumors, including ovarian cancer, colon cancer, etc. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115772130B_ABST
    Figure CN115772130B_ABST
Patent Text Reader

Abstract

The present invention provides a microtubule depolymerizing agent and a preparation method and use thereof, and relates to the field of pharmaceutical chemistry. The microtubule depolymerizing agent is a compound shown in formula I, or a salt thereof, or a stereoisomer thereof, or a hydrate thereof, or a solvate thereof, or a prodrug thereof. The microtubule protein depolymerizing agent is a microtubule protein depolymerizing agent at the colchicine binding site, and its anti-tumor activity depends on the hydroxamic acid group; the compound has a good inhibitory effect on a variety of tumor cells and has a broad-spectrum anti-tumor effect; and it also shows a good inhibitory effect on drug-resistant tumor cells; the compound can be used to prepare drugs for treating tumors and drug-resistant tumors. At the same time, the compound has good metabolic stability, low toxic and side effects, and good safety. The compound of the present invention overcomes the defects of existing microtubule protein depolymerizing agents, such as large toxic and side effects, and poor effects on drug-resistant tumors, and has good application prospects. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to a microtubule depolymerizing agent, a preparation method and application thereof. Background Art

[0002] Malignant tumors are one of the major diseases that threaten human health, and the treatment of tumors has always been closely watched by the world. The World Health Organization announced that in 2018, there were approximately 18.1 million new cancer cases worldwide, and the number of deaths reached 9.6 million, and the number of new tumor cases continued to rise every year. Data from my country's National Cancer Center showed that the number of new cases of malignant cancer in China in 2017 was 3.8 million. In recent years, with the continuous improvement of molecular biology technology and further understanding of the pathogenesis of tumors at the cellular and molecular levels, as well as the rapid development of technologies such as combinatorial chemistry, structure-based drug design and computer science, tumor biotherapy has made great progress and entered the era of molecular targeted therapy. Among them, microtubule-targeted drugs are widely used in the treatment of human tumors, and have good therapeutic effects on solid tumors and hematological malignancies.

[0003] Microtubules are dynamic filamentous cytoskeletal proteins composed of α-tubulin and β-tubulin, and are important targets for tumor treatment. Drugs targeting microtubules, namely tubulin binders, are currently a very successful class of chemotherapy drugs for treating tumors. They disrupt the microtubule dynamics balance during the mitotic phase of tumor cells, affect the formation of mitotic spindles, stop cell division, and promote tumor cell apoptosis. Tubulin binders include tubulin depolymerizers and tubulin polymerizers. Among them, tubulin inhibitors that bind to the colchicine site, vinblastine site, maytansine site, and pironetin site are tubulin depolymerizers; tubulin inhibitors that bind to the taxane site and laulimalide / pelorusideA site are tubulin polymerizers. Tubulin binders are currently a very successful class of chemotherapy drugs for treating tumors, but they have large toxic side effects, and their effectiveness is affected by multidrug resistance, so their application is limited.

[0004] In addition, most tubulin-binding agents are natural products or their synthetic derivatives, which are large in molecular weight and complex in structure, making them difficult to synthesize and modify. Tubulin inhibitors at the colchicine site have a small molecular weight and are easier to modify in structure, which is expected to improve their drug resistance, anti-tumor activity, pharmacokinetic properties, and reduce toxic side effects. So far, no colchicine-site tubulin depolymerizing agents with a hydroxamic acid structure have been reported. Summary of the invention

[0005] The purpose of the present invention is to provide a colchicine binding site microtubule depolymerizing agent with anti-tumor activity, in particular a microtubule depolymerizing agent dependent on hydroxamic acid, and a preparation method and use thereof.

[0006] The present invention provides a compound represented by formula I, or a salt thereof, or a stereoisomer thereof, or a hydrate thereof, or a solvate thereof, or a prodrug thereof:

[0007]

[0008] in,

[0009] R 1 , R 2 are independently selected from hydrogen, C 1 ~C 8 alkyl;

[0010] R 3 , R 4 are independently selected from hydrogen, C 1 ~C 8 Alkyl, 5-6 membered aryl; or, R 3 , R 4 Connected to form a 3- to 10-membered cycloalkyl group;

[0011] R 5 Selected from C 1 ~C 8 Alkoxy, hydroxy, -N(H)R 6 ;

[0012] R 6 Selected from hydrogen, hydroxyl, amino;

[0013] When R 1 Selected from methyl, R 2 Selected from methyl, R 3 and R 4 When both are hydrogen, R 5 Not selected from C 2 Alkoxy or N(H)OH.

[0014] Further,

[0015] R 1 , R 2 are independently selected from hydrogen, C 1 ~C 3 alkyl;

[0016] R 3 , R 4 are independently selected from hydrogen, C 1 ~C 4 Alkyl, phenyl; or, R 3 , R 4 Connect to form a 4- to 6-membered cycloalkyl group;

[0017] R 5 Selected from C 1 ~C2 Alkoxy, hydroxyl, -NH 2 、-N(H)OH、-N(H)NH 2 ;

[0018] When R 1 Selected from methyl, R 2 Selected from methyl, R 3 and R 4 When both are hydrogen, R 5 Not selected from C 2 Alkoxy or N(H)OH.

[0019] Furthermore, the compound is as shown in Formula II:

[0020]

[0021] in,

[0022] R 1 Selected from hydrogen or C 1 ~C 3 alkyl;

[0023] R 2 Selected from C 1 ~C 3 alkyl;

[0024] R 3 , R 4 are independently selected from hydrogen, C 1 ~C 4 Alkyl, phenyl; or, R 3 , R 4 connected to form a 4- to 6-membered cycloalkyl group; and R 3 , R 4 Not simultaneously selected from hydrogen.

[0025] Furthermore, the compound is as shown in Formula III:

[0026]

[0027] in,

[0028] R 3 , R 4 are independently selected from hydrogen, C 1 ~C 4 Alkyl, phenyl; or, R 3 , R 4 connected to form a 4- to 6-membered cycloalkyl group; and R 3 , R 4 Not simultaneously selected from hydrogen.

[0029] Further,

[0030] R3 , R 4 are independently selected from hydrogen, methyl, propyl, butyl, isopropyl, and phenyl; or, R 3 , R 4 connected to form a 4- to 6-membered cycloalkyl group; and R 3 , R 4 Not simultaneously selected from hydrogen.

[0031] Furthermore, the compound is as shown in Formula IV:

[0032]

[0033] in,

[0034] R 3 , R 4 are independently selected from hydrogen, C 1 ~C 4 Alkyl, phenyl; or, R 3 , R 4 connected to form a 4- to 6-membered cycloalkyl group; and R 3 , R 4 Not simultaneously selected from hydrogen.

[0035] Furthermore, the compound is one of the following compounds:

[0036]

[0037]

[0038] The present invention also provides the use of the aforementioned compound, or its salt, or its stereoisomer, or its hydrate, or its solvate, or its prodrug in the preparation of a microtubule protein depolymerizing agent;

[0039] Preferably, the tubulin depolymerizing agent is a tubulin depolymerizing agent that binds to the colchicine site of tubulin.

[0040] The present invention also provides the use of the aforementioned compound, or a salt thereof, or a stereoisomer thereof, or a hydrate thereof, or a solvate thereof, or a prodrug thereof in the preparation of a drug for treating tumors and / or drug-resistant tumors;

[0041] Preferably, the tumor is ovarian cancer, colon cancer, colorectal cancer, acute myeloid leukemia, acute monocytic leukemia, breast cancer, cervical cancer, liver cancer, kidney cancer, lung cancer, myelomonocytic leukemia, or peripheral lymphoma.

[0042] The present invention also provides a drug, which is a preparation prepared with the aforementioned compound, or its salt, or its stereoisomer, or its hydrate, or its solvate, or its prodrug as an active ingredient, and pharmaceutically acceptable excipients or auxiliary ingredients.

[0043] The compounds and derivatives provided in the present invention can be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.

[0044] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for groups or terms in this document apply to the groups or terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art can give them should be given based on the disclosure and context.

[0045] In the present invention, the structures of the compounds all refer to structures that can exist stably.

[0046] In the present invention, the minimum and maximum values ​​of the carbon atom content in the hydrocarbon group are indicated by prefixes, for example, the prefix (C a ~C b )alkyl refers to any alkyl group containing from "a" to "b" carbon atoms. Thus, for example, C 1 ~C 8 Alkyl refers to a straight or branched chain alkyl group containing 1 to 8 carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, n-butyl, n-pentyl, isopentyl, and neopentyl; 1 ~C 8 The alkoxy group refers to an alkoxy group containing 1 to 8 carbon atoms.

[0047] The present invention provides a compound that can be used as a tubulin depolymerizing agent. The tubulin depolymerizing agent is a tubulin depolymerizing agent at the colchicine binding site, and its anti-tumor activity depends on the hydroxamic acid group; the compound has a good inhibitory effect on a variety of tumor cells and has a broad-spectrum anti-tumor effect; and also shows a good inhibitory effect on drug-resistant tumor cells; the compound can be used to prepare drugs for treating tumors and drug-resistant tumors. At the same time, the compound has good metabolic stability, small toxic and side effects, and good safety. The compound of the present invention overcomes the defects of existing tubulin depolymerizing agents, such as large toxic and side effects and poor effects on drug-resistant tumors, and has good application prospects.

[0048] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0049] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The effects of compound 7b, paclitaxel and colchicine on the microtubule shape of A2780S cells; A2780S cells were treated with control (DMSO), paclitaxel (100nM), colchicine (100nM) and 7b (3, 10 and 30nM) for 16h, respectively. The images were obtained at ×400 magnification.

[0051] Figure 2 The effects of compounds 8b-14b, paclitaxel and colchicine on the microtubule shape of A2780S cells; A2780S cells were treated with control (DMSO), paclitaxel (100nM), colchicine (100nM) and 8b-14b (30nM) for 16h, respectively. The images were obtained at ×400 magnification.

[0052] Figure 3 The antitumor activity of compounds 11b, 12b, 14b and paclitaxel on C26 transplanted tumor model. Compounds 11b, 12b, 14b were orally administered once every two days; paclitaxel was injected into the tail vein once a week. A is the effect of each group of compounds on the tumor volume of mice. The tumor volume was measured with a vernier caliper every two days. The volume is mm 3 =(π / 6)×length×width×width; B is the effect of each group of compounds on mouse tumors.

[0053] Figure 4 The effects of compound 12b, paclitaxel and colchicine on microtubule shape and microtubule polymerization in A2780S cells. A shows that A2780S cells were treated with control (DMSO), paclitaxel (100nM), colchicine (100nM), 12b (1, 3, 10 and 30nM) for 16h, and the images were obtained by magnification of ×400. B shows that control (DMSO), colchicine (5μM) and 12b (5 and 10μM) were co-incubated with tubulin (3mg / ml) at 37°C, and the absorbance at 340nm was monitored every 1 minute for 55 minutes.

[0054] Figure 5 Competition experiments of compound 12b (0, 0.2, 1, 5 and 25 μM), vincristine (5, 25 μM) and colchicine (5 μM) on A2780S cells.

[0055] Figure 6is the in vivo antitumor activity of compound 12b in A2780S and A2780 / T xenograft tumor models. A and D are the inhibition of the growth volume of A2780S and A2780T tumors by the compound (the tumor volume was measured every two days with a vernier caliper, volume (mm 3 )=(π / 6)×length×width×width); B and E are the effects of the compounds on the body weight of tumor-bearing mice during the treatment process (the changes in mouse body weight were measured every two days); C and F are the tumor weights of tumor-bearing mice after sacrifice, P<0.01**, P<0.001***, P<0.0001****, t test vs Control, t test. DETAILED DESCRIPTION

[0056] The raw materials and equipment used in the specific embodiments of the present invention are all known products, which are obtained by purchasing commercial products. The raw materials, reagents and solvents used for synthesis are all analytically pure and are pretreated or used directly according to the requirements of use. The manufacturers of 0.2mmTLC silica gel plate and 60-100 mesh silica gel are all Qingdao Ocean Chemical Plant.

[0057] Cell and Animal Origin:

[0058] Human ovarian cancer cells A2780S and A2780 / T, human colon cancer cells HCT116, human colorectal adenocarcinoma cells HT29, human acute myeloid leukemia cells MOLM-13, human breast cancer cell lines MCF-7 and MCF-7 / ADR, human cervical cancer cells Hela, human liver cancer cells HepG2 and Huh-7, human renal clear cell adenocarcinoma cells 786-O, human large cell lung cancer cells H460, human breast cancer cells MDA-MB-231, human acute monocytic leukemia cells THP-1, human myelomonocytic leukemia cells MV4-11, human Epstein-Barr virus-infected mantle cell peripheral lymphoma cells JVM-2 and mouse colon cancer cells C26 were purchased from the American Type Culture Collection (ATCC), and human B lymphoma cells Ramos were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All the above cell lines were cultured and maintained by the cell bank of the State Key Laboratory of Biotherapy, Sichuan University, and were identified in 2017.

[0059] SPF female 6-7 week old BALB / c mice, athymic nude mice and NOD-SCID mice were purchased from Beijing Huafukang Biotechnology Co., Ltd., and female 7-8 week old SD rats were purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

[0060] Example 1. Preparation of various compounds that can be used as tubulin depolymerizing agents

[0061] The synthetic route of the compound is as follows:

[0062]

[0063] Reagents and conditions: (a) chloromethyl methyl ether (MOMCl), NaH, DMF, 0℃-rt, 3h; (b) N 2 H 4 ·H 2 O,Pd / C(10%),N 2 ,MeOH,rt,overnight; (c)(i)(CHO) n ,MeONa,MeOH,rt,overnight; (ii)NaBH 4 ,reflux,2h;(d)(i)4-Chloro-2-methylquinazoline,cat.conc HCl / (Me) 2 CHOH,(Me) 2 CHOH,rt,4h; (ii)4mol / L HCl / 1,4-dioxane,EA,rt,2h; (e)Appropriate bromide,Cs 2 CO 3 ,DMF,rt(7a-10a,11a and 13a)or 100℃(12a and 14a),overnight;(f)50%(w / w)NH 2 OH / H 2 O aq,NaOH,CH 2 Cl 2 / MeOH(1:2),0℃-rt,2h;(g)NaOH,EtOH,H 2 O, DCM, rt, 3-4h; (h) NH 3 ·H 2 O,MeOH,pressure tube,90℃,12h; (i)N 2 H 4 ·H 2 O,MeOH,pressure tube,90℃,5h.

[0064] 1. Synthesis of intermediates

[0065] (1) Synthesis of Methoxy-2-(methoxymethoxy)-4-nitrobenzene (Intermediate 3)

[0066]

[0067] Commercially available 2-methoxy-5-nitrophenol (16.9 g, 100 mmol) was dissolved in 250 mL of DMF, cooled to 0 °C, and 60% NaH (7.7 g, 200 mmol, 2 eq.) was slowly added. After half an hour of reaction, chloromethyl methyl ether (MOMCl, 15.2 mL, 200 mmol, 2 eq.) was slowly added dropwise to the reaction system. After the addition was complete, the reaction was transferred to room temperature to continue the reaction. TLC monitored the reaction (PET: EA = 2: 1, v / v). After the reaction was complete, the reaction solution was slowly poured into 2.5 L of water, and a large amount of yellow solid precipitated. The solid was filtered, and the filter cake was slurried with anhydrous ethanol, filtered, and vacuum dried to obtain a light yellow solid product (intermediate 3) with a yield of 74%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=8.6Hz,1H),7.91(s,1H),7.23(d,J=8.9Hz,1H),5.30(s,2H),3.93(s,3H),3.42(s,3H).

[0068] (2) Synthesis of 4-methoxy-3-(methoxymethoxy)aniline (Intermediate 4)

[0069]

[0070] Intermediate 3 (14 g, 66 mmol) was dissolved in 120 mL of methanol, 10% palladium carbon (702 mg, 0.1 eq.) and hydrazine hydrate (32 mL, 10 eq.) were added, nitrogen was replaced, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TLC (DCM: MeOH = 20: 1, v / v). After the reaction was complete, the mixture was filtered through diatomaceous earth, concentrated under reduced pressure, extracted with ethyl acetate and water, and the organic phases were combined and dried over anhydrous sodium sulfate. The solvent was then dried to obtain a light yellow oily product (Intermediate 4) with a yield of 87%. 1 H NMR (400 MHz, DMSO-d 6 )δ6.68(d,J=8.5Hz,1H),6.37(d,J=2.5Hz,1H),6.16(dd,J=8.5,2.5Hz,1H),5.05(s,2H),4.67(s,2H),3.63(s,3H),3.38(s,3H).

[0071] (3) Synthesis of 4-methoxy-3-(methoxymethoxy)-N-methylaniline (Intermediate 5)

[0072]

[0073] MeONa (14.7 g, 273 mmol, 5 eq.) was dissolved in 150 mL of methanol and cooled to 0 °C in an ice bath. Intermediate 4 (10 g, 54.6 mmol, 1 eq.) and paraformaldehyde (2.3 g, 76.4 mmol, 1.4 eq.) were added and reacted at room temperature overnight. Then NaBH 4 (2.2 g, 57.3 mmol, 1.05 eq.). Heat to reflux for 2 h, monitor the reaction by TLC (DCM: MeOH = 20: 1, v / v). After the reaction is complete, concentrate the reaction solution under reduced pressure, then add 500 mL of NaOH (1 mol / L) aqueous solution to the concentrated reaction solution, and a large amount of white solid precipitates. Filter and vacuum dry to obtain a white solid powder (Intermediate 5) with a yield of 75%. 1 H NMR (400 MHz, DMSO-d 6 )δ6.77(d,J=8.6Hz,1H),6.34(d,J=2.6Hz,1H),6.12(dd,J=8.6,2.6Hz,1H),5. 24–5.20(m,1H),5.08(s,2H),3.64(s,3H),3.39(s,3H),2.61(d,J=5.2Hz,3H).

[0074] (4) Synthesis of 2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenol (Intermediate 6)

[0075]

[0076] Intermediate 5 (8.08 g, 41 mmol, 1 eq.) and 4-chloro-2-methylquinazoline (7.32 g, 41 mmol, 1 eq.) were added to 250 mL of isopropanol, and then 0.5 mL of hydrochloric acid / isopropanol solution was added and stirred at room temperature. As the reaction proceeded, a large amount of light yellow solid precipitated. After the reaction was complete, the mixture was filtered off by TLC monitoring (PET:EA=2:1, v / v). The obtained filter cake was treated with saturated NaHCO 3 The solution was alkalized, and the obtained solution was extracted with 150 mL × 3 of ethyl acetate, and the organic phases were combined. The organic phase was concentrated under reduced pressure, and 15.4 mL of hydrochloric acid / 1,4-dioxane solution (4 mol / L, 62 mmol, 1.5 eq.) was added to the concentrated organic phase. As the reaction proceeded, a large amount of yellow solid was generated. TLC monitoring (DCM: MeOH = 20: 1, v / v), after the reaction was complete, suction filtration was performed, and the filter cake was added to saturated NaHCO 3The solution was stirred, and a large amount of white solid was generated, which was filtered again. The filter cake was recrystallized with anhydrous ethanol and dried in vacuo to obtain an off-white solid powder (Intermediate 6) with a yield of 79%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.31(s,1H),7.64(d,J=8.0Hz,1H),7.59(ddd,J=8.3,6.1,2.0Hz,1H),7.12–7.03(m,2H),6. 94(dd,J=7.1,1.9Hz,1H),6.64(dd,J=7.4,2.2Hz,2H),3.79(s,3H),3.47(s,3H),2.58(s,3H).

[0077] 2. Synthesis of target compounds

[0078] (1) Synthesis of Ethyl 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)acetate (target compound 7a)

[0079]

[0080] In a 100 mL round-bottom flask, 1.77 g of intermediate 6 (6 mmol, 1 eq.) and 3.90 g of Cs 2 CO 3 (12mmol, 2eq.) was dissolved in 20mL DMF, stirred at room temperature for 0.5h, and then 1.10g ethyl bromoacetate (synthesized target compound 7a, 6.6mmol, 1.1eq.) was added dropwise to the reaction system. Stirred at room temperature overnight, monitored by TLC (DCM: MeOH = 20:1, v / v), after the reaction was complete, the mixture was dried under reduced pressure. 40mL of dichloromethane was added to the dried solid to dissolve the product in dichloromethane, filtered, and the filtrate was concentrated and purified by Flash column separation to obtain a light yellow solid 7a with a yield of 86%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.64(d,J=7.7Hz,1H),7.61–7.55(m,1H),7.08–7.03(m,1H),7.00(d,J=4.7Hz,1H),6.98(d,J=5.5Hz,1H),6.92(d,J=2.4Hz,1H ),6.75(dd,J=8.5,2.4Hz,1H),4.74(s,2H),4.02(q,J=7.1Hz,2H),3.80(s,3H),3.48(s,3H),2.58(s,3H),1.10(t,J=7.1Hz,3H).13 C NMR (100 MHz, DMSO-d 6 )δ168.88,162.76,161.47,152.15,148.39,148.09,141.39,132.28,127.89,126.16,124.51,11 9.41,114.73,113.46,112.52,65.86,60.97,56.24,42.72,26.60,14.40.HRMS(ESI,m / z):calcd for C 21 H 23 N 3 O 4 [M+H] + 382.1761, found:382.1767.

[0081] (2) Synthesis of 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)acetic acid (target compound 7c)

[0082]

[0083] 190.7 mg of compound 7a (0.5 mmol, 1 eq.) was added to a 50 mL round-bottom flask and dissolved in 10 mL of dichloromethane. 197.5 mg of NaOH was dissolved in 0.5 mL of water and 2 mL of ethanol, and the resulting NaOH solution was added to the round-bottom flask and stirred at room temperature for 3-4 h. After the reaction was complete, the pH was adjusted to 6-7, and the mixture was dried under reduced pressure. 20 mL of dichloromethane was added to the dried solid to dissolve the product in dichloromethane, and the filtrate was filtered. The filtrate was mixed with fine silica gel and separated and purified by a Flash column to obtain a light yellow solid 7c with a yield of 72%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=8.2Hz,1H),7.61–7.56(m,1H),7.09–7.04(m,1H),7.01(d,J=8.7Hz,1H),6.97(d,J=8.0Hz,1H),6.8 4–6.79(m,2H),4.91(q,J=6.7Hz,1H),3.81(s,3H),3.47(s,3H),3.46(s,3H),2.59(s,3H),1.44(d,J=6.7Hz,3H). 13 C NMR (100 MHz, DMSO-d 6)δ170.86,162.76,161.46,152.02,149.09,147.81,141.36,132.28,127.77,126.26,124 .49,118.35,114.71,112.84,111.92,67.21,56.15,42.68,26.56.HRMS(ESI,m / z):calcd for C 19 H 19 N 3 O 4 [M+H] + 354.1448, found:354.1456.

[0084] (3) Synthesis of N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)acetamide (target compound 7b)

[0085]

[0086] 190.7 mg of compound 7a (0.5 mmol, 1 eq.) was added to a 50 mL round-bottom flask, 9 mL of DCM:MeOH (v / v, 1:2) was added to the reaction flask, the reaction system was cooled to 0 °C, and then 0.5 mL of 50% (w / w) NH 2 OH / H 2 O solution (15mmol, 30eq.), 0.2g NaOH (10mmol, 10eq.) was added after 5 minutes. The reaction was continued for 2h at this temperature. After the reaction was completed under TLC monitoring (DCM:MeOH=20:1, v / v), the reaction solution was poured into 90mL water, the pH was adjusted to 7-8 with glacial acetic acid, and extracted with 40mL×3 ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, the solvent was dried under reduced pressure, and the solid was recrystallized with anhydrous ethanol and dried under vacuum to obtain a white solid powder product 7b with a yield of 85%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),9.03(s,1H),7.65(d,J=8.0Hz,1H),7.61–7.56(m,1H),7.10–7.05(m,1H),7.02(dd,J=10.4,5.2 Hz,2H),6.96(d,J=8.6Hz,1H),6.72(dd,J=8.5,2.1Hz,1H),4.40(s,2H),3.80(s,3H),3.49(s,3H),2.59(s,3H). 13C NMR (100 MHz, DMSO-d 6 )δ164.51,162.80,161.46,152.13,148.83,148.31,141.38,132.34,127.92,126.17,124 .57,119.58,114.72,113.33,113.06,67.52,56.22,42.75,26.60.HRMS(ESI,m / z):calcd for C 19 H 20 N 4 O 4 [M+H] + 369.1557, found:369.1560.

[0087] (4) Synthesis of 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)acetamide (target compound 7d)

[0088]

[0089] 190.7 mg of compound 7a (0.5 mmol, 1 eq.) was added to a 35 mL pressure tube, and 6 mL of methanol and 1.16 mL of NH 3 ·H 2 O, (7.5 mmol, 15 eq.), heated and stirred at 90°C for 12 h, monitored by TLC (DCM: MeOH = 20:1, v / v). After the reaction was complete, the reaction solution was dried under reduced pressure, and the residue was separated and purified by Flash column to obtain a light yellow solid 7d with a yield of 79%. 1 HNMR (400 MHz, DMSO-d 6 )δ7.64(d,J=7.8Hz,1H),7.61–7.56(m,1H),7.32(d,J=27.6Hz,2H),7.09–7.04(m,1H),6.99(dd,J= 10.2,7.9Hz,3H),6.73(dd,J=8.5,2.4Hz,1H),4.39(s,2H),3.81(s,3H),3.49(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6)δ166.89,162.79,161.44,152.13,148.76,148.30,141.39,132.32,127.92,126.17,124.57 ,119.56,114.72,113.34,113.10,70.56,68.01,56.24,42.75,26.61.HRMS(ESI,m / z):calcd for C 19 H 20 N 4 O 3 [M+H] + 353.1608, found:353.1607.

[0090] (5) Synthesis of 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)acetohydrazide (target compound 7e)

[0091]

[0092] 190.7 mg of compound 7a (0.5 mmol, 1 eq.) was added to a 35 mL pressure tube, followed by 5 mL of methanol and 0.98 mL of N 2 H 4 ·H 2 O, (20 mmol, 40 eq.), heated and stirred at 90 °C for 5 h, monitored by TLC (DCM: MeOH = 20:1, v / v). After the reaction was complete, the reaction solution was dried under reduced pressure, and the residue was separated and purified by Flash column to obtain white solid powder 7e with a yield of 81%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.11(s,1H),7.64(d,J=7.6Hz,1H),7.61–7.56(m,1H),7.06(dd,J=6.8,1.3Hz,1H),6.99(dd,J=9.7,5 .5Hz,3H),6.74(dd,J=8.5,2.4Hz,1H),4.42(s,2H),4.27(s,2H),3.80(s,3H),3.49(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6)δ166.89,162.79,161.44,152.13,148.76,148.30,141.39,132.32,127.92,126.17,124.57 ,119.56,114.72,113.34,113.10,70.56,68.01,56.24,42.75,26.61.HRMS(ESI,m / z):calcd forC 19 H 21 N 5 O 3 [M+H] + 368.1717, found:368.1717.

[0093] (6) Synthesis of target compounds 8a-14a

[0094] The preparation methods of compounds 8a-11a and 13a are consistent with the preparation method of compound 7a. The preparation methods of compounds 12a and 14a are slightly different from the preparation method of compound 7a. In comparison, 12a and 14a require higher temperatures and equivalent ratios than other similar compounds. The specific preparation methods are as follows:

[0095] In a 100 mL round-bottom flask, 1.77 g of compound 6 (6 mmol, 1 eq.) and 3.90 g of Cs 2 CO 3 (12mmol, 2eq.) was dissolved in 20mL DMF, stirred at room temperature for 0.5h, and then 2.51g ethyl 2-bromoisovalerate (synthesized 12a, 12mmol, 2eq.) or 3.73g ethyl 1-bromocyclobutanecarboxylate (synthesized 14a, 18mmol, 3eq.) was added dropwise to the reaction system. Stirred overnight at 100°C, monitored by TLC (DCM:MeOH=20:1, v / v) after the reaction was complete, and then dried under reduced pressure. 40mL of dichloromethane was added to the dried residue to dissolve the product in dichloromethane, filtered, and the filtrate was concentrated and purified by Flash column to obtain light yellow solids 12a and 14a.

[0096] Methyl2-(2-methoxy-5-(methyl(2-methyl-6,7-dihydroquinazolin-4-yl)amino)phenoxy)propanoate (target compound 8a)

[0097]

[0098] White solid, yield 92%. 1 H NMR (400 MHz, DMSO-d 6)δ7.67–7.62(m,1H),7.61–7.56(m,1H),7.09–7.04(m,1H),7.01(d,J=8.7Hz,1H),6.97(d,J=8.0Hz,1H),6.84– 6.79(m,2H),4.91(q,J=6.7Hz,1H),3.81(s,3H),3.47(s,3H),3.46(s,3H),2.59(s,3H),1.44(d,J=6.7Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ172.00,162.77,161.42,152.11,148.47,147.74,141.31,132.31,127.87,126.08,124.55,11 9.78,114.68,113.70,113.64,73.05,56.24,52.24,42.75,26.57,18.48.HRMS(ESI,m / z):calcd for C 21 H 23 N 3 O 4 [M+H] + 382.1761,found:382.1770.

[0099] Ethyl2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)pentanoate (target compound 9a)

[0100]

[0101] Pale yellow waxy solid, yield 90%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=7.8Hz,1H),7.62–7.55(m,1H),7.07–7.00(m,2H),6.98(d,J=7. 9Hz,1H),6.84(dd,J=8.6,2.4Hz,1H),6.75(d,J=2.4Hz,1H),4.70(dd,J=7.2, 5.4Hz,1H),3.91–3.86(m,1H),3.81(s,3H),3.47(s,3H),2.59(s,3H),1.84– 1.70(m,2H),1.45–1.36(m,2H),1.02(t,J=7.1Hz,3H),0.88(t,J=7.4Hz,3H). 13C NMR (100 MHz, DMSO-d 6 )δ171.13,162.77,161.44,152.17,148.49,148.08,141.37,132.28,127.92,126.05,124.49,119.75,114. 70,113.87,113.68,76.83,60.93,56.34,42.73,34.59,26.57,18.25,14.33,13.94.HRMS(ESI,m / z):calcd forC 24 H 29 N 3 O 4 [M+H] + 424.2231, found:424.2240.

[0102] Ethyl 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)hexanoate (target compound 10a)

[0103]

[0104] Pale yellow oil, yield 91%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=7.5Hz,1H),7.61–7.56(m,1H),7.08–7.00(m,2H),6.97(d,J=8.0Hz,1H),6. 84(dd,J=8.6,2.5Hz,1H),6.75(d,J=2.4Hz,1H),4.69(t,J=6.3Hz,1H),3.88(dd,J=10.6 ,7.1Hz,2H),3.81(s,3H),3.47(s,3H),2.58(s,3H),1.78(dd,J=15.3,7.1Hz,2H),1.35( dd,J=14.4,7.0Hz,2H),1.31–1.23(m,2H),1.02(t,J=7.1Hz,3H),0.85(t,J=7.1Hz,3H). 13 C NMR (100 MHz, DMSO-d 6)δ171.13,162.78,161.44,152.15,148.49,148.06,141.36,132.32,127.92,126.05,124.51,119.78,114.70, 113.89,113.71,77.02,60.94,56.36,42.75,32.19,27.01,26.59,22.13,14.35,14.21.HRMS(ESI,m / z):calcd for C 25 H 31 N 3 O 4 [M+H] + 438.2387, found:438.2386.

[0105] Ethyl2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanoate (target compound 11a)

[0106]

[0107] Pale yellow solid powder, yield 87%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.66(d,J=7.8Hz,1H),7.62–7.57(m,1H),7.06(dd,J=11.5,4.9Hz,2H),7.04–6.98(m,2H),6.55(d,J=2. 4Hz,1H),3.90(q,J=7.1Hz,2H),3.78(s,3H),3.47(s,3H),2.59(s,3H),1.35(s,6H),1.01(t,J=7.1Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.22,162.83,161.53,152.18,150.87,145.08,141.18,132.36,127.99,126.13,124.56,121.2 1,118.91,114.63,114.03,80.35,61.21,56.21,42.67,26.57,24.93,14.14.HRMS(ESI,m / z):calcd for C 23 H 27 N 3 O 4 [M+H]+ 410.2074,found:410.2079.

[0108] Ethyl2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanoate (target compound 12a)

[0109]

[0110] Pale yellow waxy solid, yield 85%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.67–7.63(m,1H),7.61–7.56(m,1H),7.07–7.00(m,2H),6.97(d,J=7.8Hz, 1H),6.84(dd,J=8.6,2.5Hz,1H),6.72(d,J=2.5Hz,1H),4.47(d,J=5.6Hz,1H), 3.93–3.82(m,2H),3.81(s,3H),3.47(s,3H),2.58(s,3H),2.12(dq,J=13.5,6 .8Hz,1H),1.01(t,J=7.1Hz,3H),0.98(d,J=6.8Hz,3H),0.94(d,J=6.8Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.50,162.78,161.44,152.15,148.52,148.38,141.41,132.31,127.92,126.04,124.52,119.74,114. 70,114.06,113.63,81.84,60.79,56.48,42.75,31.54,26.58,18.57,18.04,14.38.HRMS(ESI,m / z):calcd forC 24 H 29 N 3 O 4 [M+H] + 424.2231, found:424.2235.

[0111] Methyl2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-phenylacetate (target compound 13a)

[0112]

[0113] White solid powder, yield 92%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.64(d,J=7.7Hz,1H),7.60–7.56(m,1H),7.50–7.44(m,2H),7.38(d,J=4.8Hz,3H),7.00(t,J=9.9Hz,2H),6.94–6 .85(m,2H),6.79(dd,J=8.3,1.9Hz,1H),5.95(d,J=21.6Hz,1H),3.82(s,3H),3.46(s,3H),3.44(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.08,162.75,161.46,152.12,148.70,147.23,141.34,135.74,132.33,129.43,129.10,127.89,12 6.01,124.60,120.17,114.68,114.49,113.91,78.39,56.42,52.60,42.73,26.61.HRMS(ESI,m / z):calcd forC 26 H 25 N 3 O 4 [M+H] + 444.1918, found:444.1924.

[0114] Ethyl1-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxylate (compound 14a)

[0115]

[0116] Transparent waxy solid, yield 91%. 1 H NMR (400 MHz, DMSO-d 6)δ7.66(d,J=7.9Hz,1H),7.61–7.56(m,1H),7.09–7.01(m,2H),6.96(d,J= 8.2Hz, 1H), 6.86 (dd, J=8.6, 2.4Hz, 1H), 6.09 (d, J=2.4Hz, 1H), 3.92 (q, J= 7.1Hz,2H),3.80(s,3H),3.43(s,3H),2.58(s,3H),2.37(ddd,J=12.9,8.8 ,3.9Hz,2H),2.24–2.15(m,2H),1.85–1.70(m,2H),1.01(t,J=7.1Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ171.99,162.82,161.50,152.11,148.21,145.50,141.17,132.36,127.92,126.02,124.56,119.06,1 14.64,113.82,112.68,79.91,61.34,56.18,42.64,31.86,26.53,14.21,13.48.HRMS(ESI,m / z):calcd for C 24 H 27 N 3 O 4 [M+H] + 422.2074,found:422.2037.

[0117] (7) Synthesis of target compounds 8c-14c

[0118] The preparation methods of compounds 8c-14c are consistent with the preparation method of compound 7c.

[0119] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)propanoic acid (target compound 8c)

[0120]

[0121] Pale yellow solid, yield 70%. 1 H NMR (400 MHz, DMSO-d 6)δ7.84(d,J=8.2Hz,1H),7.76–7.66(m,1H),7.18–7.12(m,1H),7.04(d,J=8.7Hz,1H),7.00(d,J=2.4Hz,1H),6.90(d,J=8. 4Hz,1H),6.85(dd,J=8.5,2.4Hz,1H),4.85(q,J=6.7Hz,1H),3.82(s,3H),3.57(s,3H),2.67(s,3H),1.46(d,J=6.7Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.00,161.49,161.14,149.14,148.26,146.78,139.50,133.76,126.62,125.66,123.91 ,119.38,113.63,113.59,113.18,72.90,56.28,43.41,24.59,18.52.HRMS(ESI,m / z):calcd for C 20 H 21 N 3 O 4 [M+H] + 368.1605, found:368.1603.

[0122] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)pentanoic acid (target compound 9c)

[0123]

[0124] Pale yellow solid, yield 91%. 1 H NMR (400 MHz, DMSO-d 6 )δ8.05(d,J=8.3Hz,1H),7.85(t,J=7.6Hz,1H),7.26(t,J=7.8Hz,1H),7.14(dd,J=5.3,3.1Hz,2H),7.07(d,J=8.5Hz,1H),6.78(d,J=8 .6Hz,1H),4.76(t,1H),3.86(s,3H),3.71(s,3H),2.78(s,3H),1.87–1.75(m,2H),1.42(dd,J=14.7,7.3Hz,2H),0.88(t,J=7.3Hz,3H). 13 C NMR (100 MHz, DMSO-d6 )δ172.35,160.84,160.00,150.12,148.77,140.78,137.48,135.45,127.21,126.95,119.50,119.3 1,113.88,113.11,112.44,76.37,56.45,44.24,34.40,22.31,18.38,13.99.HRMS(ESI,m / z):calcd for C 22 H 25 N 3 O 4 [M+H] + 396.1918, found:396.1922.

[0125] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)hexanoic acid (target compound 10c)

[0126]

[0127] Light grey solid, yield 92%. 1 H NMR (400 MHz, DMSO-d 6 )δ8.04(d,J=8.3Hz,1H),7.85(t,J=7.6Hz,1H),7.26(t,J=7.8Hz,1H),7.14(d,J=7.2Hz,2H),7.06(d,J=8.4Hz,1H),6.79(d,J=8.6Hz,1H),4.75(t ,1H),3.86(s,3H),3.71(s,3H),2.77(s,3H),1.87–1.77(m,2H),1.37(dd ,J=11.5,5.3Hz,2H),1.29(dd,J=13.4,6.6Hz,2H),0.85(t,J=7.1Hz,3H). 13 CNMR (100MHz, DMSO-d 6 )δ172.34,160.84,160.01,150.14,148.76,140.79,137.48,135.47,127.22,126.95,119.52,119.32,1 13.90,113.17,112.45,76.60,56.47,44.24,32.01,27.18,22.34,22.16,14.26.HRMS(ESI,m / z):calcd for C 23 H27 N 3 O 4 [M+H] + 410.2074,found:410.2075.

[0128] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanoic acid (target compound 11c)

[0129]

[0130] Pale yellow solid, yield 85%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.64(d,J=7.6Hz,1H),7.61–7.55(m,1H),7.07–6.96(m,3H),6.86(dd,J=8.6,2.4 Hz,1H),6.71(d,J=2.4Hz,1H),3.77(s,3H),3.46(s,3H),2.58(s,3H),1.34(s,6H). 13 C NMR (100 MHz, DMSO-d 6 )δ162.79,161.36,152.05,150.55,140.81,132.37,127.85,126.21,124.52,120.00,118.2 0,114.54,113.63,100.00,80.66,56.17,49.06,42.69,26.55,25.30.HRMS(ESI,m / z):calcd for C 21 H 23 N 3 O 4 [M+H] + 382.1761, found:382.1766.

[0131] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanoic acid (target compound 12c)

[0132]

[0133] Pale yellow solid, yield 98%. 1 H NMR (400 MHz, DMSO-d6 )δ7.64(d,J=7.9Hz,1H),7.61–7.54(m,1H),7.04(t,J=7.1Hz,1H),6.98(d,J=8.1Hz,1H),6.93(d,J=8.6Hz,1H),6.87(d,J=2.3Hz,1H),6.6 5(dd,J=8.5,2.3Hz,1H),4.40(d,J=4.9Hz,1H),3.79(s,3H),3.46(s,3H),2.58(s,3H),2.16(td,J=13.4,6.7Hz,1H),0.99(t,J=7.0Hz,6H). 13 C NMR (100 MHz, DMSO-d 6 )δ172.49,162.72,161.40,151.79,149.05,148.49,141.21,132.37,127.61,126.17,124.56,119.0 2,114.60,113.68,113.37,82.25,56.44,42.69,31.32,26.44,19.03,18.04.HRMS(ESI,m / z):calcd for C 22 H 25 N 3 O 4 [M+H] + 396.1918, found:396.1922.

[0134] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-phenylacetic acid (target compound 13c)

[0135]

[0136] Pale yellow solid, yield 94%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=8.2Hz,1H),7.57(t,J=7.6Hz,1H),7.51(d,J=6.7Hz,2H),7.43–7.31(m,3H),7.03(d,J=2.3Hz,1H),6.96(t ,J=7.9Hz,2H),6.85(d,J=8.5Hz,1H),6.66(dd,J=8.5,2.3Hz,1H),5.84(s,1H),3.81(s,3H),3.45(s,3H),2.59(s,3H).13 C NMR (100 MHz, DMSO-d 6 )δ171.16,162.56,161.39,151.28,148.79,147.78,141.00,136.62,132.49,129.05,128.91,127.85,127 .22,126.13,124.67,119.63,114.47,114.28,113.64,78.77,56.38,42.75,26.29.HRMS(ESI,m / z):calcd forC 25 H 23 N 3 O 4 [M+H] + 430.1761, found:430.1751.

[0137] 1-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxylic acid (target compound 14c)

[0138]

[0139] Pale yellow solid, yield 94%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=8.1Hz,1H),7.58(t,J=7.3Hz,1H),7.07(t,J=7.4Hz,1H),6.98(dd,J=12.6,8.7Hz,2H),6.77(d,J=7.8Hz,1 H),6.21–6.14(m,1H),3.79(s,3H),3.44(s,3H),2.58(s,3H),2.40–2.32(m,2H),2.19–2.08(m,2H),1.83–1.73(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.89,162.75,161.44,151.93,148.12,145.85,140.95,132.41,127.74,126.16,124.64,11 8.44,114.55,113.54,112.52,79.75,56.12,42.61,31.91,26.50,13.63.HRMS(ESI,m / z):calcd for C 22 H23 N 3 O 4 [M+H] + 394.1761, found:394.1761.

[0140] (8) Synthesis of target compounds 8b-14b

[0141] The preparation method of compounds 8b-14b is consistent with the preparation method of compound 7b.

[0142] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)propena mide (target compound 8b)

[0143]

[0144] White solid, yield 87%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),8.97(s,1H),7.65(d,J=8.1Hz,1H),7.58(t,J=7.2Hz,1H),7.07(t,J=7.3Hz,1H),6.97(dd,J=14.1,5.2H z,3H),6.74(dd,J=8.5,2.3Hz,1H),4.58(q,J=6.4Hz,1H),3.80(s,3H),3.48(s,3H),2.59(s,3H),1.36(d,J=6.5Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ167.68,162.80,161.47,152.14,148.96,147.75,141.34,132.34,127.92,126.16,124.59 ,119.95,114.80,114.70,113.59,74.03,56.27,42.73,26.60,18.86.HRMS(ESI,m / z):calcd for C 20 H 22 N 4 O 4 [M+H] + 383.1714, found:383.1715.

[0145] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)pentana mide (target compound 9b)

[0146]

[0147] Off-white solid, yield 79%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),8.96(s,1H),7.65(d,J=8.1Hz,1H),7.58(t,J=7.3Hz,1H), 7.06(t,J=7.5Hz,1H),6.98(dd,J=8.1,6.1Hz,2H),6.92(d,J=2.3Hz,1H),6 .74(dd,J=8.6,2.3Hz,1H),4.42(t,J=6.4Hz,1H),3.80(s,3H),3.48(s,3H) ,2.59(s,3H),1.78–1.63(m,2H),1.39–1.27(m,2H),0.84(t,J=7.4Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ167.03,162.79,161.47,152.14,148.92,148.10,141.33,132.34,127.92,126.15,124.59,119.8 6,114.68,114.68,113.69,77.67,56.32,42.72,34.78,26.60,18.16,14.01.HRMS(ESI,m / z):calcd for C 22 H 26 N 4 O 4 [M+H] + 411.2027, found:411.2029.

[0148] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)hexana mide (target compound 10b)

[0149]

[0150] Pale yellow solid, yield 77%. 1H NMR (400 MHz, DMSO-d 6 )δ10.71(s,1H),8.94(s,1H),7.65(d,J=7.7Hz,1H),7.61–7.56(m,1H),7.09– 7.03(m,1H),6.99(d,J=3.7Hz,1H),6.97(d,J=4.4Hz,1H),6.92(d,J=2.4Hz,1 H),6.75(dd,J=8.6,2.4Hz,1H),4.40(t,J=6.4Hz,1H),3.79(s,3H),3.48(s,3 H),2.59(s,3H),1.78–1.67(m,2H),1.30–1.22(m,4H),0.83(t,J=7.0Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ167.01,162.77,161.47,152.06,148.96,148.07,141.31,132.37,127.86,126.16,124.61,119.89,1 14.76,114.67,113.71,77.91,56.33,42.74,32.33,26.94,26.58,22.22,14.29.HRMS(ESI,m / z):calcd for C 23 H 28 N 4 O 4 [M+H] + 425.2183, found:425.2188.

[0151] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanamide (target compound 11b)

[0152]

[0153] Pale yellow solid, yield 70%. 1 H NMR (400 MHz, DMSO-d 6)δ10.68(s,1H),8.83(s,1H),7.62(d,J=8.3Hz,1H),7.55(t,J=7.5Hz,1H),7.01(dd,J=13.0,8.1Hz,2H), 6.92(dd,J=12.2,5.4Hz,2H),6.79(d,J=2.2Hz,1H),3.76(s,3H),3.44(s,3H),2.55(s,3H),1.23(s,6H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.65,162.80,161.37,152.11,151.74,144.69,140.99,132.35,127.93,126.21,124.51 ,121.88,121.04,114.53,113.91,82.09,56.34,42.72,26.58,25.20.HRMS(ESI,m / z):calcd for C 21 H 24 N 4 O 4 [M+H] + 397.1870, found:397.1869.

[0154] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanamide (target compound 12b)

[0155]

[0156] White solid powder, yield 71%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),8.98(s,1H),7.62(d,J=8.2Hz,1H),7.55(t,J=7.5Hz,1H ),7.03(t,J=7.6Hz,1H),6.93(dd,J=11.3,8.7Hz,3H),6.66(dd,J=8.5,1. 8Hz,1H),4.07(d,J=6.9Hz,1H),3.76(s,3H),3.44(s,3H),2.55(s,3H),2 .07(dq,J=13.3,6.7Hz,1H),0.95(d,J=6.7Hz,3H),0.86(d,J=6.8Hz,3H). 13C NMR (100 MHz, DMSO-d 6 )δ166.43,162.80,161.47,152.03,148.92,148.60,141.31,132.38,127.83,126.17,124.63,119.8 5,114.78,114.65,113.73,83.27,56.40,42.73,31.45,26.56,18.63,18.58.HRMS(ESI,m / z):calcd for C 22 H 26 N 4 O 4 [M+H] + 411.2017, found:411.2024.

[0157] N-hydroxy-2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-phenylacetamide (target compound 13b)

[0158]

[0159] Off-white solid powder, yield 79%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.63(d,J=8.0Hz,1H),7.57(t,J=7.3Hz,1H),7.46(d,J=6.7Hz,2H),7.37–7.28(m,3H),7.01–6.92(m ,3H),6.86(d,J=8.4Hz,1H),6.67(d,J=7.7Hz,1H),5.59(s,1H),3.81(s,3H),3.43(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ165.55,162.75,161.50,152.07,149.12,147.39,141.32,137.25,132.34,128.80,128.63,127.84,127 .61,126.04,124.63,120.24,115.66,114.66,113.76,79.20,56.42,42.66,26.58.HRMS(ESI,m / z):calcd for C 25 H 24 N 4 O4 [M+H] + 445.1870, found:445.1871.

[0160] N-hydroxy-1-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxamide (target compound 14b)

[0161]

[0162] White solid powder, yield 77%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),8.78(s,1H),7.64(d,J=8.2Hz,1H),7.58(t,J=7.6Hz,1H) ,7.05(dd,J=16.5,8.0Hz,2H),6.96(d,J=8.5Hz,1H),6.86(dd,J=8.6,2.2H z,1H),6.22(d,J=2.2Hz,1H),3.79(d,J=5.2Hz,3H),3.46(s,3H),2.58(s,3 H),2.24(t,J=9.1Hz,2H),2.00(dd,J=21.8,9.8Hz,2H),1.71–1.56(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ168.69,162.77,161.42,152.13,148.85,145.13,140.98,132.33,127.87,126.22,124.55,119.1 4,114.53,114.07,113.58,80.76,56.16,42.56,31.50,26.56,19.01,13.44.HRMS(ESI,m / z):calcd for C 22 H 24 N 4 O 4 [M+H] + 409.1870, found:409.1872.

[0163] (9) Synthesis of target compounds 8d-14d

[0164] The preparation methods of compounds 8d-14d are consistent with the preparation method of compound 7d.

[0165] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)propanamide (target compound 8d)

[0166]

[0167] White solid, yield 81%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.64(d,J=7.5Hz,1H),7.61–7.56(m,1H),7.34(s,1H),7.21(s,1H),7.08–7.03(m,1H),6.99(d,J=8.6Hz,2H),6.94(d,J=2 .5Hz,1H),6.75(dd,J=8.6,2.5Hz,1H),4.55(q,J=6.7Hz,1H),3.81(s,3H),3.47(s,3H),2.58(s,3H),1.36(d,J=6.6Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.57,162.78,161.45,152.15,148.75,147.94,141.37,132.32,127.94,126.12,124.57 ,119.79,114.71,114.51,113.51,75.57,56.25,42.72,26.60,18.89.HRMS(ESI,m / z):calcd for C 20 H 22 N 4 O 3 [M+H] + 367.1765, found:367.1766.

[0168] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)pentanamide (target compound 9d)

[0169]

[0170] Off-white solid, yield 72%. 1 H NMR (400 MHz, DMSO-d 6)δ7.65(d,J=7.7Hz,1H),7.62–7.55(m,1H),7.36(s,1H),7.22(s,1H),7.08 –7.03(m,1H),6.99(d,J=8.6Hz,2H),6.92(d,J=2.4Hz,1H),6.76(dd,J=8.6, 2.4Hz,1H),4.43(dd,J=6.9,5.3Hz,1H),3.81(s,3H),3.48(s,3H),2.58(s, 3H),1.76–1.62(m,2H),1.38(dq,J=14.5,7.3Hz,2H),0.85(t,J=7.4Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.02,162.77,161.44,152.10,148.71,148.31,141.34,132.34,127.91,126.11,124.56,119.6 7,114.68,114.35,113.60,79.29,56.31,42.71,34.83,26.59,18.27,14.09.HRMS(ESI,m / z):calcd for C 22 H 26 N 4 O 3 [M+H] + 395.2078,found:395.2085.

[0171] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)hexanamide (target compound 10d)

[0172]

[0173] Pale yellow solid, yield 74%. 1 H NMR (400 MHz, DMSO-d 6)δ7.65(dd,J=8.3,0.7Hz,1H),7.61–7.56(m,1H),7.36(s,1H),7.22(s,1H),7.08–7. 03(m,1H),6.99(d,J=8.6Hz,2H),6.92(d,J=2.5Hz,1H),6.76(dd,J=8.6,2.5Hz,1H),4 .43(t,J=6.1Hz,1H),3.81(s,3H),3.48(s,3H),2.58(s,3H),1.73(dt,J=6.9,4.8Hz,2 H), 1.34 (dt, J=15.3, 6.7Hz, 2H), 1.25 (dd, J=14.8, 7.1Hz, 2H), 0.83 (t, J=7.2Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 )δ173.00,162.77,161.44,152.14,148.74,148.29,141.37,132.32,127.93,126.10,124.55,119.71,1 14.69,114.46,113.63,79.53,56.32,42.71,32.37,27.06,26.60,22.28,14.29.HRMS(ESI,m / z):calcd for C 23 H 28 N 4 O 3 [M+H] + 409.2234,found:409.2242.

[0174] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanamide (target compound 11d)

[0175]

[0176] Pale yellow solid, yield 75%. 1 H NMR (400 MHz, DMSO-d 6)δ7.65(d,J=8.0Hz,1H),7.62–7.55(m,1H),7.43(s,1H),7.22(s,1H),7.07(d,J=8.6Hz,1H),7.06–7.0 2(m,1H),7.01–6.93(m,2H),6.80(d,J=2.4Hz,1H),3.80(s,3H),3.48(s,3H),2.58(s,3H),1.24(s,6H). 13 CNMR (100MHz, DMSO-d 6 )δ176.36,162.81,161.41,152.19,151.48,144.86,141.07,132.31,128.00,126.19,124.51 ,121.52,120.37,114.57,113.87,82.27,56.29,42.68,26.60,24.87.HRMS(ESI,m / z):calcd for C 21 H 24 N 4 O 3 [M+H] + 381.1921, found:381.1925.

[0177] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanamide (target compound 12d)

[0178]

[0179] Pale yellow solid, yield 70%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.65(d,J=8.0Hz,1H),7.58(t,J=7.1Hz,1H),7.37(s,1H),7.24(s,1H),7.0 8–7.02(m,1H),6.99(dd,J=8.2,4.5Hz,2H),6.95(d,J=2.0Hz,1H),6.73(dd,J =8.4,2.0Hz,1H),4.20(d,J=5.5Hz,1H),3.82(s,3H),3.48(s,3H),2.59(s,3H ), 2.11(td,J=12.8,6.3Hz,1H), 0.98(d,J=6.7Hz,3H), 0.93(d,J=6.8Hz,3H). 13C NMR (100 MHz, DMSO-d 6 )δ172.34,162.77,161.44,152.13,148.86,148.71,141.40,132.31,127.93,126.12,124.56,119.6 2,114.69,114.44,113.67,84.65,56.41,42.70,31.33,26.60,18.94,18.20.HRMS(ESI,m / z):calcd for C 22 H 26 N 4 O 3 [M+H] + 395.2078,found:395.2078.

[0180] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-phenylacetamide (target compound 13d)

[0181]

[0182] White solid, yield 76%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.63(d,J=7.6Hz,1H),7.61–7.54(m,2H),7.46(dd,J=7.7,1.4Hz,2H),7.40–7.28(m,4H),7.01–6.93(m,3 H),6.86(d,J=8.3Hz,1H),6.70(dd,J=8.6,2.5Hz,1H),5.60(s,1H),3.82(s,3H),3.42(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ171.21,162.74,161.48,152.10,148.98,147.45,141.33,137.35,132.33,128.75,128.67,127.88,127 .65,126.02,124.61,120.15,115.44,114.68,113.68,80.65,56.41,42.67,26.60.HRMS(ESI,m / z):calcd for C 25 H 24 N 4 O 3[M+H] + 429.1921, found:429.1917.

[0183] 1-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxamide (target compound 14d)

[0184]

[0185] White solid, yield 75%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.64(dd,J=8.3,0.8Hz,1H),7.61–7.55(m,1H),7.21(s,1H),7.12(s,1H),7.09–7.01(m,2H),6.96(d,J=8.4Hz,1H),6.85(dd,J=8.6,2.5Hz ,1H),6.21(d,J=2.5Hz,1H),3.81(s,3H),3.45(s,3H),2.58(s,3H),2. 25(ddd,J=12.8,8.8,3.9Hz,2H),2.05–1.95(m,2H),1.71–1.57(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ174.23,162.77,161.44,152.13,148.70,145.26,141.03,132.33,127.91,126.15,124.58,11 9.02,114.58,113.73,113.56,81.26,56.13,42.59,31.23,26.58,13.46.HRMS(ESI,m / z):calcd for C 22 H 24 N 4 O 3 [M+H] + 393.1921, found:393.1924.

[0186] (10) Synthesis of target compounds 8e-14e

[0187] The preparation methods of compounds 8e-14e are consistent with the preparation method of compound 7e.

[0188] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)propanehydrazide (target compound 8e)

[0189]

[0190] White solid, yield 86%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.14(s,1H),7.65(d,J=7.6Hz,1H),7.62–7.55(m,1H),7.09–7.04(m,1H),6.98(dd,J=8.1,5.9Hz,2H),6.92(d ,J=2.4Hz,1H),4.63(q,J=6.5Hz,1H),4.17(s,2H),3.81(s,3H),3.48(s,3H),2.59(s,3H),1.35(d,J=6.6Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.17,162.79,161.41,152.15,148.84,147.78,141.33,132.30,127.94,126.14,124.56 ,119.85,114.69,114.54,113.59,74.50,56.27,42.76,26.61,18.90.HRMS(ESI,m / z):calcd for C 20 H 23 N 5 O 3 [M+H] + 382.1874, found:382.1878.

[0191] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)pentanehydrazide(target compound 9e)

[0192]

[0193] White solid, yield 64%. 1 H NMR (400 MHz, DMSO-d 6)δ9.15(s,1H),7.65(d,J=8.0Hz,1H),7.59(t,J=7.4Hz,1H),7.08–7.03(m,1H),6.98(t,J=8.9Hz,2H),6.88(d,J=2.2Hz,1H),6.79(dd,J=8.5,2. 2Hz,1H),4.49(t,J=6.3Hz,1H),4.11(s,2H),3.81(s,3H),3.48(s,3H),2 .59(s,3H),1.76–1.65(m,2H),1.37–1.27(m,2H),0.83(t,J=7.4Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ169.62,162.77,161.39,152.13,148.79,148.14,141.32,132.29,127.91,126.12,124.53,119.7 2,114.67,114.36,113.70,78.13,56.33,42.75,34.84,26.59,18.17,14.03.HRMS(ESI,m / z):calcd for C 22 H 27 N 5 O 3 [M+H] + 410.2187, found:410.2197.

[0194] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)hexanehydrazide(target compound 10e)

[0195]

[0196] Pale yellow solid, yield 69%. 1 H NMR (400 MHz, DMSO-d 6)δ9.15(s,1H),7.65(d,J=8.2Hz,1H),7.59(t,J=7.5Hz,1H),7.06(t,J=7 .6Hz,1H),6.98(t,J=9.2Hz,2H),6.89(d,J=2.3Hz,1H),6.79(dd,J=8.6,2 .3Hz,1H),4.48(t,J=6.3Hz,1H),4.13(s,2H),3.81(s,3H),3.48(s,3H), 2.59(s,3H),1.77–1.64(m,2H),1.31–1.19(m,4H),0.83(t,J=6.9Hz,3H). 13 CNMR (100MHz, DMSO-d 6 )δ169.58,162.78,161.40,152.16,148.82,148.12,141.34,132.29,127.93,126.11,124.52,119.76,1 14.68,114.46,113.72,78.39,56.34,42.75,32.40,26.95,26.60,22.24,14.26.HRMS(ESI,m / z):calcd for C 23 H 29 N 5 O 3 [M+H] + 424.2343,found:424.2349.

[0197] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanehydrazide (target compound 11e)

[0198]

[0199] Grey solid, yield 61%. 1 H NMR (400MHz, DMSO) δ9.12(s,1H),7.65(d,J=8.0Hz,1H),7.59(t,J=7.4Hz,1H),7.08–7.02(m,2H),6.97(dd, J=8.7,2.9Hz,2H),6.82(d,J=2.5Hz,1H),4.24(s,2H),3.81(s,3H),3.49(s,3H),2.58(s,3H),1.26(s,6H). 13 C NMR (100 MHz, DMSO-d6 )δ172.87,162.68,161.34,151.85,144.64,140.87,132.50,127.53,126.27,124.63,121.95 ,121.14,114.44,113.91,108.17,82.28,56.40,42.79,26.40,25.16.HRMS(ESI,m / z):calcd for C 21 H 25 N 5 O 3 [M+H] + 396.2030,found:396.2029.

[0200] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanehydrazide(target compound 12e)

[0201]

[0202] Pale yellow solid, yield 67%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.15(s,1H),7.65(d,J=7.7Hz,1H),7.59(t,J=7.5Hz,1H),7.08–7.03(m, 1H),6.97(t,J=9.7Hz,2H),6.89(d,J=2.4Hz,1H),6.76(dd,J=8.6,2.4Hz,1H ),4.19(d,J=6.6Hz,1H),4.10(s,2H),3.81(s,3H),3.48(s,3H),2.59(s,3H) ,2.08(dq,J=13.4,6.7Hz,1H),0.96(d,J=6.7Hz,3H),0.87(d,J=6.8Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ169.00,162.77,161.39,152.16,148.77,148.64,141.35,132.28,127.94,126.13,124.53,119.6 5,114.69,114.37,113.77,83.57,56.43,42.76,31.44,26.62,18.68,18.53.HRMS(ESI,m / z):calcd for C 22 H27 N 5 O 3 [M+H] + 410.2187, found:410.2188.

[0203] 2-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)-2-phenylacetohydrazide(target compound 13e)

[0204]

[0205] Off-white solid, yield 67%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.41(s,1H),7.64(d,J=8.3Hz,1H),7.57(t,J=7.5Hz,1H),7.46(d,J=7.2Hz,2H),7.36–7.28(m,3H),6.96(dd,J=15.5,8 .2Hz,3H),6.85(d,J=8.5Hz,1H),6.74(d,J=8.5Hz,1H),5.65(s,1H),4.22(s,2H),3.83(s,3H),3.43(s,3H),2.58(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ168.15,162.75,161.44,152.11,149.04,147.36,141.31,137.18,132.31,128.80,128.66,127.89,127 .62,126.02,124.61,120.20,115.34,114.66,113.81,79.64,56.43,42.73,26.60.HRMS(ESI,m / z):calcd for C 25 H 25 N 5 O 3 [M+H] + 444.2030,found:444.2028.

[0206] 1-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carbohydrazide (target compound 14e)

[0207]

[0208] Pale yellow solid, yield 70%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.09(s,1H),7.64(d,J=8.1Hz,1H),7.58(t,J=7.4Hz,1H),7.05(dd,J= 13.1,8.2Hz,2H),6.94(d,J=8.4Hz,1H),6.90–6.83(m,1H),6.23(d,J=1. 8Hz,1H),4.13(s,2H),3.81(s,3H),3.46(s,3H),2.58(s,3H),2.28(t,J= 8.7Hz, 2H), 2.04 (dd, J=23.4, 12.1Hz, 2H), 1.64 (dt, J=18.4, 9.7Hz, 2H). 13 CNMR (100MHz, DMSO-d 6 )δ170.93,162.75,161.36,152.16,148.93,145.18,140.97,132.29,127.92,126.16,124.52,11 9.28,114.55,114.20,113.63,80.96,56.19,42.63,31.51,26.60,13.43.HRMS(ESI,m / z):calcd for C 22 H 25 N 5 O 3 [M+H] + 408.2030, found:408.2037.

[0209] Example 2: Preparation of a Compound Having a Hydroxamic Acid Structure

[0210] The synthetic route of the compound is as follows:

[0211]

[0212] Reagents and conditions: (a) (i) 4-chloro-2-methylquinazoline, cat.conc HCl / (Me) 2 CHOH,(Me) 2 CHOH,rt,4h; (ii)4mol / L HCl / 1,4-dioxane,EA,rt,2h; (b)Appropriate bromide,Cs 2 CO 3,DMF,rt(16)or 100℃(17 and 18),overnight; (c)50%(w / w)NH 2 OH / H 2 O aq,NaOH,CH 2 Cl 2 / MeOH (1:2, v / v), 0℃-rt, 2h.

[0213] 1. Synthesis of intermediates

[0214] (1) Synthesis of 2-methoxy-5-((2-methylquinazolin-4-yl)amino)phenol (Intermediate 15)

[0215]

[0216] The preparation method of intermediate 15 is similar to that of intermediate 6. Intermediate 4 (3.66 g, 20 mmol, 1 eq.) and 4-chloro-2-methylquinazoline (3.57 g, 20 mmol, 1 eq.) were added to 150 mL of isopropanol, and then 0.25 mL of hydrochloric acid / isopropanol solution was added and stirred at room temperature. As the reaction proceeded, a large amount of light yellow solid precipitated. After the reaction was complete, the mixture was filtered by TLC monitoring (PET:EA=2:1, v / v). The obtained filter cake was treated with saturated NaHCO 3 The solution was alkalized, and the obtained solution was extracted with 100 mL × 3 of ethyl acetate, and the organic phases were combined. The organic phase was concentrated under reduced pressure, and hydrochloric acid / 1,4-dioxane solution (4 mol / L, 7.51 mL, 1.5 eq.) was added to the concentrated organic phase. As the reaction proceeded, a large amount of yellow solid was generated. After the reaction was complete, the reaction was monitored by TLC (DCM: MeOH = 20:1, v / v), and the filter cake was added to saturated NaHCO 3 The solution was stirred, and a large amount of white solid was generated, which was filtered again. The filter cake was recrystallized with anhydrous ethanol and dried in vacuo to obtain the intermediate 15 as an off-white solid powder with a yield of 74%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.45(s,1H),9.02(s,1H),8.48(d,J=8.0Hz,1H),7.79–7.74(m,1H),7.66(d,J=7.7Hz,1H),7.53–7.48(m ,1H),7.44(d,J=2.5Hz,1H),7.27(dd,J=8.7,2.5Hz,1H),6.93(d,J=8.8Hz,1H),3.78(s,3H),2.49(s,3H).

[0217] 2. Synthesis of target compounds 19-21

[0218] The preparation method of compound 19-21 is similar to that of 7b. 562.6 mg of intermediate 15 (2 mmol, 1 eq.) and 1.30 g of Cs 2 CO 3 (4mmol, 2eq.) was dissolved in 10mL DMF, stirred at room temperature for 0.5h, and then 429mg ethyl 2-bromo-2-methylpropionate (synthetic intermediate 16, 2.2mmol, 1.1eq.) or 1.25g ethyl 2-bromoisovalerate (synthetic intermediate 17, 6mmol, 3eq.) or 1.24g ethyl 1-bromocyclobutanecarboxylate (synthetic intermediate 18, 6mmol, 3eq.) was added dropwise to the reaction system. Stir overnight at room temperature (intermediate 16) or 100°C (intermediates 17 and 18). After the reaction was complete, the product was dried under reduced pressure by spin drying. 20mL of dichloromethane was added to the spin-dried residue to dissolve the product in dichloromethane, and the filtrate was concentrated and purified by Flash column separation to obtain light yellow solid intermediates 16-18 with a yield of 85%-96%. Then, 191 mg of intermediate 16 (0.5 mmol, 1 eq.), 205 mg of intermediate 17 (0.5 mmol, 1 eq.) and 204 mg of intermediate 18 were weighed into three 50 mL reaction bottles, 9 mL of DCM:MeOH (1:2, v / v) was added to each reaction bottle, the reaction system was cooled to 0°C, and then 0.5 mL of 50% (w / w) NH 2 OH / H 2 O solution (15mmol, 30eq.), 0.2g NaOH (10mmol, 10eq.) was added after 5 minutes. The reaction was continued at this temperature for 2h. After the reaction was completed under TLC monitoring (DCM: MeOH = 20:1, v / v), the reaction solution was poured into 90mL water, the pH was adjusted to 7-8 with glacial acetic acid, and 40mL × 3 ethyl acetate was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, sodium sulfate was filtered out, and then vacuum dried, and the solid was recrystallized from anhydrous ethanol to obtain the target compound 19-21.

[0219] N-hydroxy-2-(2-methoxy-5-((2-methylquinazolin-4-yl)amino)phenoxy)-2-methylpropanamide (target compound 19)

[0220]

[0221] Pale yellow solid, yield 70%. 1H NMR (400 MHz, DMSO-d 6 )δ10.64(s,1H),9.58(s,1H),8.78(s,1H),8.46(d,J=8.1Hz,1H),7.78(t,J=7.2Hz,1H),7.67(d,J=8.1Hz,1H),7.64(d,J=2 .4Hz,1H),7.52(t,J=7.5Hz,1H),7.37(dd,J=8.7,2.4Hz,1H),7.03(d,J=8.8Hz,1H),3.79(s,3H),2.49(s,3H),1.49(s,6H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.90,163.50,157.98,150.69,148.86,143.25,133.17,132.52,127.64,125.56,123 .17,117.71,117.49,113.68,112.75,81.60,56.41,26.60,25.55.HRMS(ESI,m / z):calcd for C 20 H 22 N 4 O 4 [M+H] + 383.1714, found:383.1716.

[0222] N-hydroxy-2-(2-methoxy-5-((2-methylquinazolin-4-yl)amino)phenoxy)-3-methylbutanamide (target compound 20)

[0223]

[0224] White solid, yield 77%. 1 H NMR (400 MHz, DMSO-d 6)δ10.69(s,1H),9.61(s,1H),8.95(s,1H),8.46(d,J=8.1Hz,1H),7.77(t,J =7.3Hz,1H),7.67(d,J=8.0Hz,1H),7.60(s,1H),7.52(t,J=7.2Hz,1H),7.4 1(d,J=8.1Hz,1H),7.01(d,J=8.6Hz,1H),4.16(d,J=5.8Hz,1H),3.81(s,3H ), 2.50 (s, 3H), 2.19 (dd, J = 12.7, 6.3Hz, 1H), 1.02 (dd, J = 21.5, 6.4Hz, 6H). 13 C NMR (100 MHz, DMSO-d 6 )δ166.84,163.50,157.91,150.51,147.43,146.58,133.14,132.97,127.51,125.55,123.10,11 6.47,113.57,112.86,112.28,84.17,56.47,31.69,26.60,18.96,18.38.HRMS(ESI,m / z):calcd for C 21 H 24 N 4 O 4 [M+H] + 397.1870, found:397.1868.

[0225] N-hydroxy-1-(2-methoxy-5-((2-methylquinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxamide (target compound 21)

[0226]

[0227] White solid, yield 69%. 1 H NMR (400 MHz, DMSO-d 6)δ10.61(s,1H),9.65(s,1H),8.69(s,1H),8.48(d,J=8.1Hz,1H),7.79(t,J =7.5Hz,1H),7.67(d,J=8.2Hz,1H),7.53(t,J=7.4Hz,1H),7.30(d,J=2.0Hz ,1H),7.22(dd,J=8.7,2.1Hz,1H),7.00(d,J=8.7Hz,1H),3.80(s,3H),2.75 –2.67(m,2H),2.52(s,3H),2.36–2.26(m,2H),1.83(dt,J=17.2,6.9Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ169.17,163.55,157.89,146.55,143.90,133.28,132.52,127.33,125.64,123.26,11 5.40,113.62,112.53,111.44,80.56,56.23,32.09,26.52,13.86.HRMS(ESI,m / z):calcd for C 21 H 22 N 4 O 4 [M+H] + 395.1714, found:395.1714.

[0228] Example 3. Preparation of a Compound Having a Hydroxamic Acid Structure

[0229] The synthetic route of the compound is as follows:

[0230]

[0231] Reagents and conditions: (a) tri-methoxymethane, ammonium acetate, MeOH, 120℃, autoclave, 5h; (b) (i) DIPEA, PhMe, reflux, 1h; (ii) POCl 3 ,80℃,2h;(c)(i)4-methoxy-3-(methoxymethoxy)-N-methylaniline,cat.conc HCl / (Me) 2 CHOH,(Me) 2 CHOH,rt,4h; (ii)4mol / L HCl / 1,4-dioxane,EA,rt,2h; (d)Appropriate bromide,Cs2 CO 3 ,DMF,rt(26)or 100℃(27 and 28),overnight; (e)50%(w / w)NH 2 OH / H 2 O aq,NaOH,CH 2 Cl 2 / MeOH (1:2), 0℃-rt, 2h.

[0232] 1. Synthesis of intermediates

[0233] (1) Synthesis of quinazolin-4(3H)-one (Intermediate 23)

[0234]

[0235] 991 mg of ethyl 2-aminobenzoate (6 mmol, 1 eq.), 1.27 g of trimethyl orthoformate (12 mmol, 2 eq.) and 924 mg of ammonium acetate (12 mmol, 2 eq.) were added to the autoclave, and then 10 mL of methanol was added to dissolve, and the reaction was stirred at 120 ° C for 5 h. After the temperature was cooled to room temperature, the autoclave was opened, and a large amount of white solid was generated. TLC monitoring (PET: EA = 2: 1, v / v) showed that the reaction was complete, and the solid was dissolved in methanol and transferred to a round-bottom flask. The solvent was spin-dried, and 100 mL × 3 of ethyl acetate and water were added for extraction. The organic phases were combined and washed once with saturated brine, and the organic phases were dried over anhydrous sodium sulfate. The solvent was spin-dried under reduced pressure to obtain a white pure intermediate 23 with a yield of 95%. 1 H NMR (400 MHz, DMSO-d 6 )δ12.24(s,1H),8.14(dd,J=7.9,1.0Hz,1H),8.10(s,1H),7.86–7.79(m,1H),7.68(d,J=8.1Hz,1H),7.54(t,J=7.5Hz,1H).

[0236] (2) Synthesis of 4-chloroquinazoline (Intermediate 24)

[0237]

[0238] 584 mg of quinazolinone (4 mmol, 1 eq.), 1.05 mL of DIPEA (6 mmol, 1.5 eq.) and 15 mL of toluene were added to a 100 mL round-bottom flask and refluxed for 1 h. After reflux, the temperature was reduced to 80 ° C, 560 μ L of phosphorus oxychloride (6 mmol, 1.5 eq.) was slowly added dropwise, and heated and stirred at 80 ° C overnight. After the reaction was complete, the remaining phosphorus oxychloride was evaporated under reduced pressure, and the reaction solution was poured into ice water. 100 mL × 3 of dichloromethane and water were extracted, the organic phases were combined and washed with saturated brine, the organic phases were dried over anhydrous sodium sulfate, and the solid was recrystallized from anhydrous ethanol to obtain a light yellow solid as intermediate 24 with a yield of 60%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.00(s,1H),8.19(dd,J=8.0,1.1Hz,1H),8.01–7.95(m,1H),7.90(d,J=8.1Hz,1H),7.72–7.66(m,1H).

[0239] (3) Synthesis of 2-methoxy-5-(methyl(quinazolin-4-yl)amino)phenol (Intermediate 25)

[0240]

[0241] The preparation method of intermediate 25 is the same as that of intermediate 6, with a yield of 78%. 1 H NMR (400 MHz, DMSO-d 6 )δ8.69(s,1H),7.72(d,J=8.2Hz,1H),7.63(ddd,J=8.3,6.6,1.6Hz,1H),7.13(dtd,J=9.7,8.5,1.2Hz,2 H),6.92(d,J=8.5Hz,1H),6.68(d,J=2.6Hz,1H),6.61(dd,J=8.5,2.6Hz,1H),3.78(s,3H),3.47(s,3H).

[0242] 2. Synthesis of target compounds 29-31

[0243] The preparation method of compounds 29-31 is consistent with the preparation method of compounds 11b, 12b and 14b. 562.6 mg of intermediate 15 (2 mmol, 1 eq.) and 1.30 g of Cs 2 CO 3(4mmol, 2eq.) was dissolved in 10mL DMF, stirred at room temperature for 0.5h, and then 429mg ethyl 2-bromo-2-methylpropionate (synthetic intermediate 26, 2.2mmol, 1.1eq.) or 1.25g ethyl 2-bromoisovalerate (synthetic intermediate 27, 6mmol, 3eq.) or 1.24g ethyl 1-bromocyclobutanecarboxylate (synthetic intermediate 28, 6mmol, 3eq.) was added dropwise to the reaction system. The mixture was stirred overnight at room temperature (intermediate 26) or heated at 100°C (intermediates 27 and 28). After the reaction was complete, the mixture was dried under reduced pressure. 20 mL of dichloromethane was added to the spin-dried residue to dissolve the product in dichloromethane, and the product was filtered. After the filtrate was concentrated, it was separated and purified by Flash column to obtain light yellow solid intermediates 26-28 with yields of 87.5%, 92.1% and 90.8%, respectively. Then 191 mg of intermediate 26 (0.5 mmol, 1 eq.), 205 mg of intermediate 27 (0.5 mmol, 1 eq.) and 204 mg of intermediate 28 were weighed into three 50 mL reaction bottles, and 9 mL of DCM:MeOH (v / v, 1:2) was added to each reaction bottle. The reaction system was cooled to 0°C, and then 0.5 mL of 50% (w / w) NH 2 OH / H 2 O solution (15mmol, 30eq.), 0.2g NaOH (10mmol, 10eq.) was added after 5 minutes. The reaction was continued for 2h at this temperature. After the reaction was completed under TLC monitoring (DCM:MeOH=20:1, v / v), the reaction solution was poured into 90mL water, the pH was adjusted to 7-8 with glacial acetic acid, and 40mL×3 ethyl acetate was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, sodium sulfate was filtered out, and then vacuum dried. The solid was recrystallized from anhydrous ethanol to obtain the target compound 29-31.

[0244] N-hydroxy-2-(2-methoxy-5-(methyl(quinazolin-4-yl)amino)phenoxy)-2-methylpropanamide (target compound 29)

[0245]

[0246] Pale yellow solid, yield 66%. 1 H NMR (400 MHz, DMSO-d 6)δ10.62(s,1H),8.71(s,1H),7.74(d,J=7.7Hz,1H),7.68–7.62(m,1H),7.16–7.10(m,1H),7.08(d,J=8.7Hz,1H), 7.02(d,J=8.5Hz,1H),6.97(dd,J=8.6,2.6Hz,1H),6.85(d,J=2.5Hz,1H),3.81(s,3H),3.50(s,3H),1.27(s,6H). 13 C NMR (100 MHz, DMSO-d 6 )δ170.54,161.28,154.47,151.87,151.54,144.76,140.83,132.50,128.55,126.29,125 .42,121.92,121.04,116.39,113.95,82.11,56.36,42.84,25.20.HRMS(ESI,m / z):calcd for C 20 H 22 N 4 O 4 [M+H] + 383.1714, found:383.1720.

[0247] N-hydroxy-2-(2-methoxy-5-(methyl(quinazolin-4-yl)amino)phenoxy)-3-methylbutanamide (target compound 30)

[0248]

[0249] Pale yellow solid, yield 71%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.72(s,1H),8.96(s,1H),8.71(s,1H),7.74(d,J=8.2Hz,1H),7.65(t,J=7.3Hz,1H),7.15(t,J=7.4Hz,1H),7.03(d,J=8.4Hz,1H),6.97(dd ,J=5.5,3.0Hz,2H),6.73(dd,J=8.6,2.3Hz,1H),4.11(d,J=6.9Hz,1H),3.80(s,3H),3.50(s,3H),0.98(d,J=6.7Hz,3H),0.89(d,J=6.8Hz,3H). 13 C NMR (100 MHz, DMSO-d6 )δ166.33,161.35,154.45,151.49,149.04,148.65,141.14,132.51,128.48,126.26,125.53,11 9.84,116.52,114.75,113.71,83.22,56.40,42.88,31.45,18.64,18.60.HRMS(ESI,m / z):calcd for C 21 H 24 N 4 O 4 [M+H] + 397.1870, found:397.1868.

[0250] N-hydroxy-1-(2-methoxy-5-(methyl(quinazolin-4-yl)amino)phenoxy)cyclobutane-1-carboxamide (target compound 31)

[0251]

[0252] Pale yellow solid, yield 69%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.73(s,1H),8.74(d,J=28.5Hz,2H),7.74(d,J=8.0Hz,1H),7.65(t,J=7.3Hz,1H),7.19–7.11(m,1H),7.03(dd,J=13.9,8.6Hz, 2H),6.88(d,J=7.7Hz,1H),6.25(s,1H),3.81(s,3H),3.48(s,3H),2.25(dd,2H),2.01(dd,J=19.6,9.7Hz,2H),1.72–1.56(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ168.69,161.37,154.43,151.52,149.00,145.19,140.83,132.52,128.48,126.30,125.51,11 9.21,116.41,114.09,113.63,80.79,56.19,55.37,42.72,31.49,13.43.HRMS(ESI,m / z):calcd for C 21 H 22 N 4 O4 [M+H] + 395.1714, found:395.1720.

[0253] The beneficial effects of the present invention are demonstrated below through specific test examples.

[0254] Test Example 1: Study on the anti-tumor activity of the compounds of the present invention

[0255] 1. Experimental methods

[0256] (1) MTT assay for anti-tumor activity of compounds

[0257] The cells were routinely cultured in RPMI-1640 or DMEM medium containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 mg / L streptomycin at saturated humidity, 37°C, and 5% CO. 2 Culture in an incubator. When the cells are in good condition, centrifuge at 800-1200rpm (or 300g) for 3min to collect the cells (the adherent cells need to be digested with 0.25% trypsin and blown off gently). Suspend with complete medium and count. Inoculate 3000-5000 adherent cells and 15000-25000 suspended cells in each well of a 96-well plate with 100μL of cell suspension and place in a CO 2 The experimental group was added with 100 μL of culture medium containing different concentrations of the test compound (or positive control), and the blank control group was added with an equal volume of fresh culture medium containing the same amount of DMSO as the highest experimental concentration of the drug. Three parallel wells were set up in each group at 37°C and 5% CO 2 Culture in an incubator for 72 hours.

[0258] After 72 hours of drug action, add 20 μL of 5 mg / mL MTT working solution to each well, continue to culture in a 37°C incubator for 1 to 4 hours, terminate the culture, carefully aspirate the culture supernatant in the well (centrifuge first and then discard the supernatant for suspended cells), add 150 μL DMSO, place on a small horizontal shaker for 5 minutes to fully dissolve and mix the crystals, and then detect the absorbance at 570 nm on an ELISA reader. Calculate the inhibition rate of each experimental group according to inhibition rate = (blank control-drug administration) / blank control*100%. Use Graphpad prism software to fit the dose-response curve of the compound treatment concentration and its corresponding inhibition rate, and fit the IC 50 value.

[0259] (2) Study on the metabolic stability of compounds in liver microsomes

[0260] The incubation system volume was 100 μL, and the system included 0.1 M PBS, pH 7.4, NADPH generating system (1 mM NADP, 5 mM 6-phosphate glucose, 1 U / mL 6-phosphate glucose dehydrogenase, 3.3 mM MgCl 2 ); add 1 μL of 1 mg / mL methanol solution of the test compound (concentration 100 μM / L), pre-incubate in a 37°C water bath for 5 min, add 2.5 μL of various liver microsome solutions, continue to incubate at 37°C for 0, 5, 15, 30, 45 and 60 min, take out, add 200 μL of pre-cooled methanol containing 10 ng / mL of internal standard SAHA to terminate the reaction. Vortex mix for 3 min, centrifuge at 13000 rpm for 15 min, take the supernatant, and perform UFLC-MS / MS determination.

[0261] The concentration of the test compound at the incubation time point of 0 min was taken as 100%, and the concentrations at other incubation time points were compared with it to obtain the remaining percentage. The natural logarithm of the remaining percentage at each time point and the incubation time were used for linear regression to obtain the slope k, and the half-life T was calculated according to the following formula: 1 / 2 and clearance rate CL int .

[0262] T 1 / 2 =-0.693 / k;

[0263] CL int (μL / min / mg) = Ln(2)*1000 / T 1 / 2 / C 肝微粒体

[0264] (3) Immunofluorescence staining experiment

[0265] A2780S cells in good growth state were plated on a 6-well plate with a slide (cover glass) and cultured for 24 hours. After the cells were completely attached to the wall, different concentrations of the test compounds (DMSO, the compound of the present invention, paclitaxel, colchicine) were added and incubated for 16 hours. The supernatant was discarded, and the membrane was fixed with 50% methanol / 50% acetone solution for 2 minutes after washing once with PBS preheated at 37°C, and then washed once with PBS, and α-tubulin antibody dissolved in 3% BSA solution was added and incubated for 4 hours. Washed with PBS three times, 5 minutes each time, incubated with fluorescent secondary antibody and 10-fold diluted DAPI for 40 minutes, and then washed three times with PBS, sealed, observed under an immunofluorescence microscope, and obtained pictures.

[0266] (4) Microtubule dynamics experiment

[0267] PEM buffer preparation: 80 mM PIPES (adjusted to pH 6.9), 2 mM MgCl2 ,0.5 mM EGTA;

[0268] On the day of the experiment, prepare a 100 mM GTP stock solution;

[0269] Set the microplate reader program: preheat at 37°C, kinetic mode dynamic reading, 340nM wavelength, measure absorbance, measure once every 1min, a total of 60min, preheat 384-well plate;

[0270] Thaw 100mM GTP on ice, dilute it with PEM buffer to 1mM GTP solution and put it on ice for later use. Thaw 10mM compound of the present invention and colchicine on ice, and prepare the compound to be tested into two concentrations of 10 and 20μM with PEM buffer (containing 1mM GTP), and colchicine is prepared into 10μM. Take out the preheated 384-well plate from the instrument, add 10μL of control, 10μM compound to be tested, 20μM compound to be tested and 10μM Colchicine to different wells, then quickly add 10μL tubulin (3mg / mL) to each well, and quickly put it into the microplate reader for determination. After the experiment is completed, the data is plotted using Graphpad prism software.

[0271] (5) EBI competition experiment

[0272] A2780 cells were incubated with the test compounds (compounds of the present invention, vincristine, colchicine, blank control DMSO) for 2 h, EBI (100 μM) was added to the cells, and incubated for another 2 h. Total protein was lysed with immunoprecipitation lysis buffer, and then β-tubulin was subjected to Western blot analysis, with β-actin as the experimental control.

[0273] (6) Flow cytometry detection of cell cycle

[0274] The test compound of the present invention was used to treat A2780S cells at concentrations of 0, 1, 3 and 10 nM for 24 h. The cell culture fluid was collected, the cells were digested with trypsin, and centrifuged at 500G for 5 min together with the collected cell culture fluid. The cells were resuspended in PBS and washed twice, fixed with precooled 75% ethanol, and stored at -20°C. The cells were washed twice with PBS before being tested on the machine, stained with PI in the dark for about 10 min, and flow cytometry was performed. The flow cytometry results were analyzed for cell population ratio using modfit software.

[0275] (7) Flow cytometry detection of cell apoptosis

[0276] The test compound of the present invention was treated with A2780S cells at concentrations of 0, 2.5, 5 and 10 nM for 48 h. The cell culture fluid was collected, the cells were digested with trypsin, and centrifuged at 500G for 5 min together with the collected cell culture fluid. The collected cells were washed once with PBS and then washed once with 1×Binding buffer. The cells were resuspended with 1×Binding buffer to a density of 1 to 5*10 6 / mL density. Add 5μL fluorescently labeled Annexin V to 100μL cell suspension for staining. After staining at room temperature and away from light for 15 minutes, wash once with 1×Binding buffer and resuspend the cells with 200μL 1×Binding buffer. Add 5μL PI and mix gently before loading. Complete flow cytometry detection within 1 hour.

[0277] (8) Study on the pharmacokinetic properties of compounds

[0278] The compound of the present invention to be tested was dissolved in DMSO and diluted to 2 mg / mL with physiological saline. 0.2 mL of blank blood was first collected from SD rats for the "0 min" time point, and then the rats were weighed and gavage and intravenous administration were performed at a dose of 10 mg / kg. 0.2 mL of blood was collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h and 24 h after administration, and the collected blood was centrifuged at 3500 rpm for 15 min, and the supernatant plasma was collected and frozen at -20 ° C for testing.

[0279] The collected plasma samples were thawed at room temperature, vortexed and mixed evenly, and then processed with the prepared standard curve by protein precipitation, and the compound concentration was detected by LC-MS / MS. The pharmacokinetic parameters were fitted by DAS 2.0 software, and the oral bioavailability of the compound was calculated. The calculation formula is as follows:

[0280] Oral bioavailability F% = AUC after oral administration of an equal amount of drug (0-24h) / AUC after intravenous equal dose of drug (0-24h) *100%

[0281] (9) Study on the anti-tumor effect of compounds in various subcutaneous tumor models

[0282] To study the in vivo anti-tumor effects of the preferred compounds, C26, A2780S and A2780 / T transplanted tumor mouse models were established. C26 cells in the logarithmic growth phase were collected, and the single cell suspension was diluted to a certain concentration with PBS buffer for later use. When inoculating, 0.1 mL of the single cell suspension was taken and 10 7 5×10 cells were inoculated into 6-7 week old female BALB / c mice. 6The A2780S and A2780T cells were subcutaneously inoculated into 6-7 week old female BALB / c nude mice and NOD / SCID mice to establish A2780S and A2780 / T xenograft models. Then, the A2780 / T tumor mass was excised and cut into small pieces and inoculated into a new batch of NOD / SCID mice for pharmacodynamic studies. When the tumor volume of C26, A2780S and A2780 / T model mice grew to 100mm 3 At about 24 hours, the mice were randomly divided into groups, with 6 mice in each group. The animals were treated with blank control (normal saline containing 2.5% Tween-80), the compound of the present invention, PTX or Cisplatin. The tumor volume (tumor volume (mm)) was measured every two days with a vernier caliper. 3 )=π / 6×length×width×width). The weight of mice was measured every two days, and toxicity was observed. On the day of termination of the experiment, mice were killed, solid tumors were removed and weighed, and the antitumor activity of the compound was evaluated according to the formula: tumor inhibitor=(1-average tumor weight of treatment group / average tumor weight of solvent control group)×100%. This experiment was conducted in accordance with the Institutional Guide for the Care and Use of Laboratory Animals, and all experimental protocols involving mice were approved by the Animal Care and Use Committee of Sichuan University (Chengdu, Sichuan, China).

[0283] 2. Experimental results

[0284] (1) Properties of compounds 7a-7e

[0285] The present invention investigates the in vitro antiproliferative activity of compounds 7a-7e on human colon cancer cell HCT116, human ovarian cancer cell A2780S and human acute myeloid leukemia cell MOLM-13 by MTT method. Paclitaxel and colchicine are used as positive controls. The results are shown in Table 1.

[0286] Table 1. In vitro anti-tumor cell proliferation activity of compounds 7a-7e

[0287]

[0288] a The concentration of compound that achieved 50% inhibition of tumor cell proliferation. Data are presented as mean±SD from three independent experiments.

[0289] As shown in Table 1, compound 7b with a hydroxamic acid structure has the best anti-tumor cell proliferation activity and has good inhibitory activity against the proliferation of three types of cancer cells.

[0290] The anti-tumor cell proliferation activity of compound 7b against various tumor cells was compared with that of the known HDAC6 selective inhibitor SKLB-23bb, and compound 7b was screened for HDAC inhibitory activity and observed by immunofluorescence experiment. The results are shown in Tables 2, 3 and Figure 1 shown.

[0291] The structural formula of SKLB-23bb is

[0292] Table 2. Antiproliferative activity of compound 7b and SKLB-23bb against various tumor cell lines

[0293]

[0294] Table 3. Inhibitory activity of compound 7b and SKLB-23bb against HDAC1 and HDAC6

[0295]

[0296] The results showed that the compound 7b obtained by shortening the linker of SKLB-23bb from three methylene groups to one methylene group had an IC value of 14.33 for the antiproliferative activity against 18 tumor cells. 50 The anti-tumor cell proliferation activity IC of SKLB-23bb was in the range of 0.954-9.87 nM. 50 The results showed that compound 7b has a hydroxamic acid group but is not a small molecule inhibitor of HDAC target.

[0297] like Figure 1 As shown in the figure, the microtubule network in the blank control group A2780S cells was normal filamentous, and the microtubule network of the spindle of the A2780S cells treated with the microtubule polymerizer paclitaxel for 16 hours was obviously aggregated and condensed, the green fluorescence became brighter, and moved closer to the nucleus. Similar to colchicine, the shape of the A2780S cells exposed to 100nM compound 7b changed from spindle to round or irregular shape, and the microtubules depolymerized. The experimental results confirmed that compound 7b is a microtubule depolymerizing agent.

[0298] However, in vitro metabolic stability studies found that compound 7b was stably metabolized in mouse liver microsomes, but was unstable and relatively fast metabolized in human liver microsomes (Table 4). Therefore, in order to obtain a microtubule depolymerizer with excellent pharmacokinetic properties and good antitumor activity, 7b was used as the lead compound for structural optimization and further investigation of the importance of the hydroxamic acid group.

[0299] Table 4. Metabolic stability of compound 7b in mouse and human liver microsomes

[0300]

[0301] (2) Properties of compounds 8a-14e

[0302] The present invention investigates the in vitro antiproliferative activity of compounds 8a-14e on human colon cancer cell HCT116, human ovarian cancer cell A2780S and human acute myeloid leukemia cell MOLM-13 by MTT method. Paclitaxel and colchicine are used as positive controls. The results are shown in Table 5.

[0303] Table 5. In vitro anti-tumor cell proliferation activity of compounds 8a-14e

[0304]

[0305] As shown in Table 5, the IC values ​​of hydroxamic acid compounds (8b, 9b, 10b, 11b, 12b, 13b and 14b, hereinafter referred to as 8b-14b) are 50 The IC values ​​of esters (8a, 9a, 10a, 11a, 12a, 13a, and 14a), carboxylic acids (8c, 9c, 10c, 11c, 12c, 13c, and 14c), amides (8d, 9d, 10d, 11d, 12d, 13d, and 14d), and hydrazides (8e, 9e, 10e, 11e, 12e, 13e, and 14e) were subnanomolar or several nanomolar, while the IC values ​​of esters (8a, 9a, 10a, 11a, 12a, 13a, and 14a), carboxylic acids (8c, 9c, 10c, 11c, 12c, 13c, and 14c), amides (8d, 9d, 10d, 11d, 12d, 13d, and 14d), and hydrazides (8e, 9e, 10e, 11e, 12e, 13e, and 14e) were 50 The value is more than 100 times that of hydroxamic acid compounds. The IC 50 It is significantly lower than other types of compounds. This indicates that hydroxamic acid compounds have excellent anti-tumor cell proliferation activity and the hydroxamic acid group is an important pharmacophore of the target compound.

[0306] A2780S cells were treated with 8b-14b for 16 h, and then the effects of the compounds on the cell microtubule network were detected by immunofluorescence. Figure 2 As shown, the microtubule network in A2780S cells exhibited normal arrangement and organization in the absence of drug treatment. PTX (microtubule polymerizer) treatment caused microtubule fibers to polymerize near the nucleus. In contrast, the state of cells exposed to 8b-14b was the same as that of cells exposed to colchicine (microtubule depolymerizer), with obvious abnormalities in microtubule spindle formation and significant depolymerization of the microtubule network at a concentration of 30nM. The above results indicate that the antiproliferative activity of the hydroxamic acid compound 8b-14b is not due to the inhibition of HDACs, but comes from the effect on microtubules. Compound 8b-14b is a tubulin depolymerizer.

[0307] Using in vitro metabolic stability to screen compounds is an important means to determine whether a compound has the value of further research. The above-mentioned hydroxamic acid compounds 8b-14b with good in vitro anti-tumor cell proliferation activity were subjected to in vitro metabolic stability investigation. A certain concentration of compound 8b-14b was incubated with mouse and human liver microsomes, respectively. The UFLC-MS / MS determined the remaining concentration of the original drug after the specified incubation time point, and the half-life and clearance rate of the target compound in liver microsomes of different species were calculated as shown in Table 6. The results showed that compounds 9b, 10b and 13b were rapidly metabolized, while compounds 8b, 11b, 12b and 14b were metabolically stable in mouse and human liver microsomes, and their metabolic stability in human liver microsomes was better than that of compound 7b.

[0308] Similarly, the inhibitory activity of 8b-14b against HDAC was determined. As shown in Table 6, the IC values ​​of HDAC inhibitor LBH589 against HDAC1 and HDAC6 were 50 The inhibitory activity IC values ​​of compounds 8b-10b and 13b against HDAC1 were 0.5 nM and 5.6 nM, respectively. 50 All of them were higher than 1.0 μM. The inhibitory activity IC of compounds 11b, 12b and 14b on HDAC1 50 All of them were greater than 10 μM. The inhibitory activity IC of compounds 8b-14b on HDAC6 50 All of them were greater than 10 μM, indicating that compounds 11b, 12b and 14b of the present invention had almost no inhibitory activity on HDAC1 and HDAC6.

[0309] Table 6. Inhibitory activity of compounds 8b-14b against HDAC1 and HDAC6 and metabolic stability in mouse and human liver microsomes

[0310]

[0311] (3) Properties of compounds 19-21 and 29-31

[0312] Based on compounds 11b, 12b and 14b, the effects of N-methyl substitution of the amino group at the 4-position of quinazoline and methyl substitution of the amino group at the 2-position of quinazoline on the antitumor activity of the compounds were also investigated. The antiproliferative results of the compounds on tumor cells are shown in Table 7. The experimental results show that the N-methyl substitution of the amino group at the 4-position of quinazoline is crucial. The IC values ​​of compounds 11b, 12b and 14b are 50 are all in the range of several nanomolar or subnanomolar, and when the methyl group is replaced by H, the IC values ​​of compounds 19-21 are 50All of them are greater than 1 μM. In addition, when the methyl group at the 2-position of quinazoline is replaced by H, the inhibitory activity of compounds 29-31 against various tumor cells is reduced by about 2-10 times. Therefore, N-methyl substitution of the amino group at the 4-position of quinazoline and methyl substitution at the 2-position of quinazoline are very important for maintaining the antitumor activity of the compounds.

[0313] The present invention investigates the in vitro antiproliferative activity of compounds 19-21 and 29-31 on human colon cancer cell HCT116, human ovarian cancer cell A2780S and human acute myeloid leukemia cell MOLM-13 by MTT method. Paclitaxel and colchicine were used as positive controls. The results are shown in Table 7.

[0314] Table 7. In vitro anti-tumor cell proliferation activity of compounds 19-21 and 29-31

[0315]

[0316]

[0317] (4) Antitumor activity of hydroxamic acid compounds in the in vivo colon cancer C26 mouse model

[0318] Through the above in vitro antiproliferative activity and metabolic stability screening of tumor cells, microtubule compounds 11b, 12b and 14b with good in vitro activity and metabolic stability were obtained. In order to further screen compounds with excellent in vivo activity, a colon cancer C26 mouse model was established using BALB / c mice for further screening of compounds. The C26 mouse model was established by subcutaneous injection of 10 7 C26 tumor cells. When the tumor volume reaches 100mm 3 The tumor-bearing mice were randomly divided into groups (6 mice in each group). 11b and 12b were both 25 mg / kg, and 14b was 50 mg / kg, administered orally every two days. Paclitaxel was used as a positive control and was intraperitoneally administered once a week at 30 mg / kg. Figure 3 shown.

[0319] The experimental results showed that among the above compounds, compound 11b had a poor anti-tumor effect in the C26 mouse model, while compounds 12b and 14b had tumor inhibition rates of 56.7% and 43.8% respectively, while the positive drug paclitaxel had a tumor inhibition rate of 30.0% in the C26 mouse model. Therefore, compound 12b was the optimal compound.

[0320] (5) Tubulin depolymerization activity of compound 12

[0321] ① Inhibitory activity against HDACs

[0322] The hydroxamic acid functional group is an important pharmacophore of HDAC inhibitors. In order to confirm whether compound 12b still has inhibitory activity against HDAC, in addition to HDAC1 and HDAC6 that have been determined previously, compound 12b was further tested for its inhibitory activity against HDAC2-5 and HDAC7-11 subtypes, with Purinostat Mesylate as a positive control. The results are shown in Table 8. The inhibitory activity IC values ​​of compound 12b against HDAC2-5, HDAC9 and HDAC10 are 50 The inhibitory activity IC values ​​of HDAC8 and HDAC11 were all greater than 10 μM. 50 All of them are greater than 5 μM. Therefore, the anti-tumor effect of compound 12b does not come from the inhibition of HDACs. Compound 12b does not have the inhibitory activity of HDACs.

[0323] Table 8. Inhibitory activity of compound 12b against HDAC2-5 and HDAC7-11.

[0324]

[0325] a Purinostat Mesylate is an HDAC inhibitor (Yang L, et al. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research 2019 Dec 15; 25(24): 7527-7539.) and is in Phase I clinical research. It is used here as a positive control for determining HDAC enzyme inhibitory activity.

[0326] ②Study on the types of microtubule inhibition

[0327] The changes in microtubule network morphology caused by microtubule polymerization or depolymerization can be visually observed by immunofluorescence experiments. Therefore, the experiment used paclitaxel and colchicine as positive controls to explore whether the anti-tumor cell proliferation activity of compound 12b is due to its effect on microtubules and to determine whether it is a microtubule polymerizer or a microtubule depolymerizer.

[0328] like Figure 4As shown in A, the microtubule network in the blank control group A2780S cells was normal filamentous. The microtubule network of the spindle of the A2780S cells treated with the microtubule polymerizer paclitaxel for 16 hours was obviously aggregated and condensed, the green fluorescence became brighter, and moved closer to the nucleus. Similar to colchicine, the shape of the A2780S cells exposed to compound 12b changed from spindle to round or irregular shape, and microtubule depolymerization occurred in a concentration-dependent manner. The experimental results confirmed that compound 12b is a microtubule depolymerizer.

[0329] To further investigate its ability to inhibit microtubule polymerization, 5 μM colchicine was used as a positive control, and 5 and 10 μM 12b were used to investigate its effect on in vitro microtubule dynamics. Figure 4 As shown in B, like the positive control colchicine, 12b can inhibit the polymerization of tubulin, and the ability of 10 μM 12b to inhibit microtubule polymerization is higher than that of 5 μM. This study further confirms that compound 12b is a microtubule depolymerizing agent.

[0330] ③Study on the binding site with tubulin

[0331] In order to explore the binding site of compound 12b with tubulin, an EBI competition experiment was performed. EBI can cross-link with Cys239 and Cys354 of the colchicine site of β-tubulin to form an EBI and β-tubulin adduct, which migrates faster than β-tubulin in WB. Drugs that bind to the colchicine site can inhibit the formation of the adduct.

[0332] The experimental results are as follows Figure 5 As shown, EBI leads to the formation of adducts, and vincristine does not bind to the colchicine site, serving as a negative control. In A2780S cells treated with vincristine 5 and 25 μM and 100 μM EBI, only the faster-moving EBI and β-tubulin adduct bands can be detected. In A2780S cells treated with 5 μM colchicine and 100 μM EBI, only the slower-moving β-tubulin native band was detected. Compound 12b dose-dependently reduced the formation of adducts and increased the formation of β-tubulin native, consistent with the effect of colchicine. Therefore, the EBI experiment confirmed that compound 12b binds to the colchicine site of β-tubulin.

[0333] ④ Anti-tumor activity against a variety of tumor cells including drug-resistant cell lines

[0334] The anti-proliferative activity results of compound 12b on various tumor cells are shown in Table 9. Compound 12b has good anti-tumor cell proliferation activity on various solid and blood tumor cells, and its anti-tumor activity is significantly better than SKLB-23bb in the same tumor cells.

[0335] Table 9. Antiproliferative activity of compound 12b against various tumor cell lines

[0336]

[0337] Overcoming the natural or acquired drug resistance of tumor cells is a key issue in treating tumors. Preclinical or clinical studies have shown that P-gp can mediate the resistance of tumor cells to a variety of anti-tumor drugs, such as the resistance of MCF-7 / ADR overexpressing P-gp to doxorubicin and the resistance of A549 / T cell line overexpressing P-gp to paclitaxel. The expression changes of β-III tubulin are closely related to the resistance to paclitaxel. For example, β-III tubulin is overexpressed in the paclitaxel-resistant cell line (A2780 / T). In order to study whether compound 12b can overcome drug resistance, three pairs of cell lines were selected, namely human ovarian cancer cell lines A2780S (sensitive), A2780 / T (tolerant to paclitaxel), human lung cancer cell lines A549 (sensitive) and A549 / T (tolerant to paclitaxel), breast cancer cell lines MCF-7 (sensitive) and MCF-7 / ADR (tolerant to doxorubicin), and the activity of compound 12b in these sensitive cell lines and resistant cell lines was compared. The results are shown in Table 10. Compound 12b showed good antiproliferative activity against these resistant cells. Compared with paclitaxel and doxorubicin, they have extremely small resistance indexes. The above results show that compound 12b shows good antiproliferative activity against a variety of tumor cells and can overcome drug resistance caused by overexpression of P-gp and β-Ⅲ tubulin.

[0338] Table 10. In vitro antiproliferative activity of compound 12b against drug-resistant cell lines

[0339]

[0340] ⑤ Study on pharmacokinetic properties

[0341] Compound 12b is a microtubule depolymerizing agent that binds to the colchicine site, with good in vitro activity and stable metabolism. In order to better study its anti-tumor effect in vivo, the pharmacokinetic properties of compound 12b were investigated to determine the administration method and frequency of 12b. The results are shown in Table 11. The exposure amount AUC of compound 12b is 0-24h and C max The oral bioavailability F of compound 12b is 64.8%, and it can be used for tumor treatment by oral administration. In addition, the oral half-life T of 12b is 1 / 2 They were 8.91±5.82h respectively. Therefore, it can be preliminarily determined that the dosage should be once every two days.

[0342] Table 11. In vivo pharmacokinetic properties of compound 12b

[0343]

[0344] ⑥ Study on the in vivo antitumor activity of compound 12b

[0345] Human ovarian cancer A2780S and paclitaxel-resistant A2780T xenograft mouse models were established.

[0346] In the human ovarian cancer A2780S xenograft model, when the tumor volume grew to 100 mm 3 The mice were randomly divided into groups of 6. Paclitaxel and cisplatin were used as positive controls, and the blank control group was given the same volume of normal saline. All drug administration regimens and routes are shown in Table 12. The tumor inhibition rates of A2780S in the high-dose group of 12b (30 mg / kg) oral administration and 12b (15 mg / kg) intravenous administration were both above 70%, which was equivalent to the positive control efficacy of paclitaxel and cisplatin, and the low-dose group of 12b oral administration also showed significant anti-tumor effects (Tables 12 and Figure 6 In addition, during the treatment, 2 mice died in the positive control group of cisplatin, and the average body weight decreased by 15.8%, showing obvious toxicity, while the body weight of each treatment group of paclitaxel and compound decreased by less than 5%, showing no obvious toxicity. The results showed that compound 12b has a good anti-tumor effect in the A2780S xenograft model and can be administered orally.

[0347] In the paclitaxel-resistant A2780 / T xenograft model, when the tumor volume grew to 100 mm 3 The mice were randomly divided into groups of 6. Paclitaxel was used as the positive control, and the blank control group was given the same volume of normal saline. The dosing regimens and routes of all drugs are shown in Table 12. The experimental results are shown in Tables 12 and Figure 6 As shown. The tumor inhibition rate of the PTX treatment group was only 35.3%, while the tumor inhibition rate of 12b (10 mg / kg iv every other day) was 75.1%. Due to long-term administration for nearly 1 month, the tolerance of NOD / SCID mice was worse than that of BALB / c nude mice. In the later stage of treatment, the 12b treatment group showed mild weight loss. The mice in the PTX group not only suffered severe weight loss, but also 2 / 6 of the mice died during the treatment, indicating that the toxicity of 12b was significantly lower than that of PTX. The above results show that 12b has a good therapeutic effect in both PTX-sensitive and -resistant xenograft mouse models.

[0348] Table 12. In vivo antitumor activity of compound 12b against A2780S and A2780 / T xenograft tumor models.

[0349]

[0350] a Q2D, every two days; Q4D, every four days.

[0351] In summary, the present invention provides a compound that can be used as a tubulin depolymerizing agent, the tubulin depolymerizing agent is a tubulin depolymerizing agent at the colchicine binding site, and its anti-tumor activity depends on the hydroxamic acid group; the compound has a good inhibitory effect on a variety of tumor cells and has a broad-spectrum anti-tumor effect; and also shows a good inhibitory effect on drug-resistant tumor cells; the compound can be used to prepare drugs for treating tumors and drug-resistant tumors. At the same time, the compound has good metabolic stability, small toxic and side effects, and good safety. The compound of the present invention overcomes the defects of existing tubulin depolymerizing agents, such as large toxic and side effects, and poor effects on drug-resistant tumors, and has good application prospects.

Claims

1. A compound or a salt thereof, Features: The compound is one of the following compounds:

2. Use of the compound or salt thereof according to claim 1 in the preparation of a tubulin depolymerizing agent.

3. The use according to claim 2, Features: The microtubule protein depolymerizing agent is a microtubule protein depolymerizing agent that binds to the colchicine site of microtubule protein.

4. Use of the compound or salt thereof according to claim 1 in preparing a drug for treating tumors.

5. The use according to claim 4, Features: The tumor is a drug-resistant tumor.

6. The use according to claim 4 or 5, Features: The tumors are ovarian cancer, colon cancer, colorectal cancer, acute myeloid leukemia, acute monocytic leukemia, breast cancer, cervical cancer, liver cancer, kidney cancer, lung cancer, myelomonocytic leukemia, and peripheral lymphoma.

7. A drug, Features: The invention relates to a preparation prepared by taking the compound or its salt as claimed in claim 1 as an active ingredient and adding pharmaceutically acceptable auxiliary materials or supplementary ingredients.